1
|
Kerkhofs D, Helgers R, Hermes D, Steinbusch HP, Van Essen H, Leenders P, Prickaerts J, Staals J, Biessen EA, Van Oostenbrugge RJ, Foulquier S. Amlodipine limits microglia activation and cognitive dysfunction in aged hypertensive mice. J Hypertens 2023; 41:1159-1167. [PMID: 37071429 PMCID: PMC10242521 DOI: 10.1097/hjh.0000000000003445] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 02/28/2023] [Indexed: 04/19/2023]
Abstract
BACKGROUND SBP and blood pressure variability are independent risk factors for cerebral small vessel disease, a leading cause for stroke and dementia. Calcium-channel blockers are known to reduce blood pressure variability and may thus offer benefit against dementia. Beyond this effect, the impact of calcium-channel blockers on hypertension-induced neuroinflammation, and especially, microglial phenotype remains unknown. We aimed to study the ability of amlopidine to alleviate microglia inflammation, and slow down cognitive dysfunction in aged hypertensive mice. METHODS Hypertensive BPH/2J and normotensive BPN/3J mice were studied until 12 months of age. Hypertensive mice were untreated or received amlodipine (10 mg/kg per day). Blood pressure parameters were measured by telemetry and tail cuff plethysmography. Mice underwent repeated series of cognitive tasks. Brain immunohistochemistry was performed to study blood-brain barrier dysfunction and microglial pro-inflammatory phenotype (CD68 + Iba1 + cells; morphological analysis). RESULTS Amlodipine normalized SBP over the entire life span and decreased blood pressure variability. BPH/2J mice exhibited impaired short-term memory that was prevented by amlodipine at 12 months (discrimination index 0.41 ± 0.25 in amlodipine-treated vs. 0.14 ± 0.15 in untreated BPH/2J mice, P = 0.02). Amlopidine treatment of BPH/2J did not prevent blood-brain barrier leakage, a measure of cerebral small vessel disease, but limited its size. Microglia's inflammatory phenotype in BPH/2J, characterized by an increased number of Iba1 + CD68 + cells, increased soma size and shortened processes, was partly reduced by amlodipine. CONCLUSION Amlodipine attenuated the short-term memory impairment in aged hypertensive mice. Beyond its blood pressure lowering capacity, amlodipine may be cerebroprotective by modulating neuroinflammation.
Collapse
Affiliation(s)
- Danielle Kerkhofs
- Department of Neurology, Maastricht University Medical Center
- Department of Pathology
- CARIM, School for Cardiovascular Diseases
| | | | - Denise Hermes
- Department of Psychiatry and Neuropsychology
- MH&NS, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands
| | - Hellen P.J. Steinbusch
- Department of Psychiatry and Neuropsychology
- MH&NS, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands
| | | | | | - Jos Prickaerts
- Department of Psychiatry and Neuropsychology
- MH&NS, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands
| | - Julie Staals
- Department of Neurology, Maastricht University Medical Center
- CARIM, School for Cardiovascular Diseases
| | - Erik A. Biessen
- Department of Pathology
- CARIM, School for Cardiovascular Diseases
- IMCAR, Institute for Molecular Cardiology Research, RWTH Aachen, Aachen, Germany
| | - Robert J. Van Oostenbrugge
- Department of Neurology, Maastricht University Medical Center
- CARIM, School for Cardiovascular Diseases
- MH&NS, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands
| | - Sébastien Foulquier
- CARIM, School for Cardiovascular Diseases
- MH&NS, School for Mental Health and Neurosciences, Maastricht University, Maastricht, The Netherlands
- Department of Pharmacology-Toxicology, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
2
|
Quiles-Jiménez A, Gregersen I, Segers FM, Skarpengland T, Kroustallaki P, Yang K, Kong XY, Lauritzen KH, Olsen MB, Karlsen TR, Nyman TA, Sagen EL, Bjerkeli V, Suganthan R, Nygård S, Scheffler K, Prins J, Van der Veer E, Øgaard JD, Fløisand Y, Jørgensen HF, Holven KB, Biessen EA, Nilsen H, Dahl TB, Holm S, Bennett MR, Aukrust P, Bjørås M, Halvorsen B. DNA glycosylase Neil3 regulates vascular smooth muscle cell biology during atherosclerosis development. Atherosclerosis 2021; 324:123-132. [PMID: 33714552 DOI: 10.1016/j.atherosclerosis.2021.02.023] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 02/12/2021] [Accepted: 02/19/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND AIMS Atherogenesis involves a complex interaction between immune cells and lipids, processes greatly influenced by the vascular smooth muscle cell (VSMC) phenotype. The DNA glycosylase NEIL3 has previously been shown to have a role in atherogenesis, though whether this is due to its ability to repair DNA damage or to other non-canonical functions is not yet clear. Hereby, we investigate the role of NEIL3 in atherogenesis, specifically in VSMC phenotypic modulation, which is critical in plaque formation and stability. METHODS Chow diet-fed atherosclerosis-prone Apoe-/- mice deficient in Neil3, and NEIL3-abrogated human primary aortic VSMCs were characterized by qPCR, and immunohistochemical and enzymatic-based assays; moreover, single-cell RNA sequencing, mRNA sequencing, and proteomics were used to map the molecular effects of Neil3/NEIL3 deficiency in the aortic VSMC phenotype. Furthermore, BrdU-based proliferation assays and Western blot were performed to elucidate the involvement of the Akt signaling pathway in the transdifferentiation of aortic VSMCs lacking Neil3/NEIL3. RESULTS We show that Neil3 deficiency increases atherosclerotic plaque development without affecting systemic lipids. This observation was associated with a shift in VSMC phenotype towards a proliferating, lipid-accumulating and secretory macrophage-like cell phenotype, without changes in DNA damage. VSMC transdifferentiation in Neil3-deficient mice encompassed increased activity of the Akt signaling pathway, supported by cell experiments showing Akt-dependent proliferation in NEIL3-abrogated human primary aortic VSMCs. CONCLUSIONS Our findings show that Neil3 deficiency promotes atherosclerosis development through non-canonical mechanisms affecting VSMC phenotype involving activation of the Akt signaling pathway.
Collapse
Affiliation(s)
- Ana Quiles-Jiménez
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Ida Gregersen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Filip M Segers
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Pharmacology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Tonje Skarpengland
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Penelope Kroustallaki
- Department of Clinical Molecular Biology, University of Oslo, Akershus University Hospital, Lørenskog, Norway
| | - Kuan Yang
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Xiang Yi Kong
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Knut H Lauritzen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Maria B Olsen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Tom Rune Karlsen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Tuula A Nyman
- Department of Immunology, Institute of Clinical Medicine, University of Oslo, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Ellen L Sagen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Vigdis Bjerkeli
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Rajikala Suganthan
- Department of Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Ståle Nygård
- Bioinformatics Core Facility, Institute for Medical Informatics, Oslo University Hospital, Oslo, Norway
| | - Katja Scheffler
- Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - Jurriën Prins
- Einthoven Laboratory of Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, the Netherlands
| | - Eric Van der Veer
- Einthoven Laboratory of Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, the Netherlands
| | - Jonas Ds Øgaard
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Yngvar Fløisand
- Department of Hematology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Helle F Jørgensen
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - Kirsten B Holven
- Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
| | - Erik A Biessen
- Department of Pathology, University of Maastricht, Maastricht, the Netherlands
| | - Hilde Nilsen
- Department of Clinical Molecular Biology, University of Oslo, Akershus University Hospital, Lørenskog, Norway
| | - Tuva B Dahl
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Sverre Holm
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Martin R Bennett
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Addenbrooke's Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - Pål Aukrust
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Magnar Bjørås
- Department of Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
| | - Bente Halvorsen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
| |
Collapse
|
3
|
Kerkhofs D, van Hagen BT, Milanova IV, Schell KJ, van Essen H, Wijnands E, Goossens P, Blankesteijn WM, Unger T, Prickaerts J, Biessen EA, van Oostenbrugge RJ, Foulquier S. Pharmacological depletion of microglia and perivascular macrophages prevents Vascular Cognitive Impairment in Ang II-induced hypertension. Am J Cancer Res 2020; 10:9512-9527. [PMID: 32863942 PMCID: PMC7449902 DOI: 10.7150/thno.44394] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Accepted: 06/12/2020] [Indexed: 12/19/2022] Open
Abstract
Rationale: Hypertension is a major risk factor for cerebral small vessel disease, the most prevalent cause of vascular cognitive impairment. As we have shown, hypertension induced by a prolonged Angiotensin II infusion is associated with increased permeability of the blood-brain barrier (BBB), chronic activation of microglia and myelin loss. In this study we therefore aim to determine the contribution of microglia to hypertension-induced cognitive impairment in an experimental hypertension model by a pharmacological depletion approach. Methods: For this study, adult Cx3Cr1gfp/wtxThy1yfp/0 reporter mice were infused for 12 weeks with Angiotensin II or saline and subgroups were treated with PLX5622, a highly selective CSF1R tyrosine kinase inhibitor. Systolic blood pressure (SBP) was measured via tail-cuff. Short- and long-term spatial memory was assessed during an Object Location task and a Morris Water Maze task (MWM). Microglia depletion efficacy was assessed by flow cytometry and immunohistochemistry. BBB leakages, microglia phenotype and myelin integrity were assessed by immunohistochemistry. Results: SBP, heart weight and carotid pulsatility were increased by Ang II and were not affected by PLX5622. Short-term memory was significantly impaired in Ang II hypertensive mice, and partly prevented in Ang II mice treated with PLX5622. Histological and flow cytometry analysis revealed almost complete ablation of microglia and a 60% depletion of brain resident perivascular macrophages upon CSF1R inhibition. Number and size of BBB leakages were increased in Ang II hypertensive mice, but not altered by PLX5622 treatment. Microglia acquired a pro-inflammatory phenotype at the site of BBB leakages in both Saline and Ang II mice and were successfully depleted by PLX5622. There was however no significant change in myelin integrity at the site of leakages. Conclusion: Our results show that depletion of microglia and PVMs, by CSF1R inhibition prevents short-term memory impairment in Ang II induced hypertensive mice. We suggest this beneficial effect is mediated by the major decrease of pro-inflammatory microglia within BBB leakages. This novel finding supports the critical role of brain immune cells in the pathogenesis of hypertension-related cognitive impairment. An adequate modulation of microglia /PVM density and phenotype may constitute a relevant approach to prevent and/or limit the progression of vascular cognitive impairment.
Collapse
|
4
|
de Bruin RG, Shiue L, Prins J, de Boer HC, Djaramshi A, Fagg WS, van Gils JM, Katzman S, Donahue JP, van Esch H, Rabelink TJ, Kazan H, Biessen EA, Ares M, van Zonneveld AJ, van der Veer EP. Abstract 47: Quaking Post-Transcriptionally Promotes Differentiation of Monocytes Into Pro-Atherogenic Macrophages by Controling Pre-mRNA Splicing and Gene Expression. Arterioscler Thromb Vasc Biol 2016. [DOI: 10.1161/atvb.36.suppl_1.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aim:
Atherosclerosis is accelerated by excessive monocyte recruitment, influx and differentiation into pro-inflammatory macrophages. While the genome-wide mRNA expression profiles of human monocytes and pro-inflammatory macrophages are well-established, their transcriptomes are ultimately defined by factors, such as RNA-binding proteins, that modulate pre-mRNA splicing patterns and mRNA transcript abundance. This prompted us to investigate the role of the RNA-binding protein Quaking in regulating global changes in pre-mRNA splicing and mature mRNA expression as human monocytes acquire the pro-inflammatory macrophage identity.
Methods:
We employed RNA-sequencing and splicing-sensitive microarrays to determine genome-wide changes in pre-mRNA splicing and mRNA expression upon conversion of human monocytes into pro-inflammatory macrophages, including those derived from a unique Quaking haploinsufficient patient.
Results:
Using laser-capture micro-dissection and immunohistochemistry, we discovered that expression levels of Quaking mRNA and protein are low in monocytes of early human atherosclerotic lesions, but abundant in macrophages of advanced plaques. Depletion of Quaking protein using both siRNA and GapmeR technology significantly impaired monocyte adhesion and migration; delayed differentiation into pro-inflammatory macrophages while maintaining the capacity to adopt the anti-inflammatory phenotype; and diminished foam cell formation in vitro and in vivo. RNA-sequencing and microarray analysis of human monocyte and macrophage transcriptomes revealed striking changes in Quaking-dependent pre-mRNA splicing and mRNA transcript levels, with gene ontology analyses identifying an enrichment in transcripts involved in cellular migration and lipid metabolism. Furthermore, these studies uncovered common as well as novel alternatively spliced transcripts with unknown biological functions in monocytes and macrophages.
Conclusions:
Our studies illustrate a central role for Quaking in post-transcriptionally guiding pro-inflammatory macrophage identity and function.
Collapse
Affiliation(s)
| | - Lily Shiue
- Dept of Molecular, Cell and Developmental Biology, Univ of California Santa Cruz, Santa Cruz, CA
| | - Jurrien Prins
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Hetty C de Boer
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Anjana Djaramshi
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | - W. Samuel Fagg
- Dept of Molecular, Cell and Developmental Biology, Univ of California Santa Cruz, Santa Cruz, CA
| | | | - Sol Katzman
- Dept of Molecular, Cell and Developmental Biology, Univ of California Santa Cruz, Santa Cruz, CA
| | - John P Donahue
- Dept of Molecular, Cell and Developmental Biology, Univ of California Santa Cruz, Santa Cruz, CA
| | - Hilde van Esch
- Dept of Human Genetics, Leuven Univ Hosp, Leuven, Belgium
| | - Ton J Rabelink
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Hilal Kazan
- Dept of Computer Engineering, Antalya International Univ, Antalya, Turkey
| | - Erik A Biessen
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | - Manuel Ares
- Dept of Molecular, Cell and Developmental Biology, Univ of California Santa Cruz, Santa Cruz, CA
| | | | | |
Collapse
|
5
|
de Bruin RG, Shiue L, Djarmshi A, de Boer HC, Leung WY, van Gils JM, Prins J, Duijs JM, van der Zande PH, Rabelink TJ, Jukema WJ, van Esch H, Kazan H, Biessen EA, Ares M, van Zonneveld AJ, van der Veer EP. Abstract 217: Quaking Post-Transcriptionally Guides Monocyte Adhesion and Differentiation into the Pro-Inflammatory Macrophage. Arterioscler Thromb Vasc Biol 2015. [DOI: 10.1161/atvb.35.suppl_1.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
A hallmark of inflammatory diseases is the excessive recruitment and influx of monocytes to sites of tissue damage and their ensuing differentiation into macrophages. Numerous stimuli are known to induce new transcription necessary for macrophage identity, but post-transcriptional control of human macrophage differentiation is less well understood. Here, we detail our discovery that levels of the RNA-binding protein Quaking (QKI) are low in monocytes of early atherosclerotic lesions, but abundant in macrophages of advanced plaques. Specific depletion of QKI protein impaired monocyte adhesion, migration and differentiation into macrophages, and lesion formation. RNA-seq and microarray analysis of human monocyte and macrophage transcriptomes, including those of a unique QKI haploinsufficient patient, reveal developmental changes in RNA levels and alternative splicing of RNA transcripts enriched in QKI-bound sequence elements. The importance of these transcripts and requirement for QKI during differentiation illustrates a central role for QKI in post-transcriptionally guiding macrophage identity and function. These studies implicate QKI as a novel target for therapeutic intervention in inflammatory diseases.
Collapse
Affiliation(s)
| | - Lily Shiue
- Dept of Molecular, Cellular and Developmental Biology, Univ of California Santa Cruz, Santa Cruz, Netherlands
| | - Anjana Djarmshi
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | - Hetty C de Boer
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Wai Yi Leung
- Dept of Med Statistics, Leiden Univ Med Cntr, Leiden, Netherlands
| | | | - Jurrien Prins
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Jacques M Duijs
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | | | - Ton J Rabelink
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Wouter J Jukema
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Hilde van Esch
- Dept of Human Genetics, Univ Hosps Leuven, Leuven, Belgium
| | - Hilal Kazan
- Dept of Nephrology, Antalya International Univ, Antalya, Turkey
| | - Erik A Biessen
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | - Manuel Ares
- Dept of Molecular, Cellular and Developmental Biology, Univ of California Santa Cruz, Santa Cruz, CA
| | | | | |
Collapse
|
6
|
Abbas A, Gregersen I, Holm S, Daissormont I, Bjerkeli V, Krohg-Sørensen K, Skagen KR, Dahl TB, Russell D, Almås T, Bundgaard D, Alteheld LH, Rashidi A, Dahl CP, Michelsen AE, Biessen EA, Aukrust P, Halvorsen B, Skjelland M. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke 2015; 46:793-9. [PMID: 25649806 DOI: 10.1161/strokeaha.114.006516] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND AND PURPOSE Interleukin (IL)-23 is a cytokine in the IL-12 family, mainly produced by antigen-presenting cells with a central role in inflammation. We hypothesize that IL-23 is also important in atherogenesis and investigate this in a population with carotid atherosclerosis. METHODS Plasma levels of IL-23 were measured in patients with carotid artery stenosis and in healthy controls. The mRNA levels of IL-23 and its receptor, IL-23R, were measured in atherosclerotic plaques, nonatherosclerotic vessels, peripheral blood mononuclear cells, and plasmacytoid dendritic cells. RESULTS Our findings were as follows: (1) patients with carotid atherosclerosis (n=177) had significantly raised plasma levels of IL-23 when compared with healthy controls (n=24) with particularly high levels in those with the most recent symptoms. (2) mRNA levels of IL-23 and IL-23R were markedly increased in carotid plaques (n=68) when compared with nonatherosclerotic vessels (n=8-10). Immunostaining showed colocalization to plaque macrophages. (3) Patients with carotid atherosclerosis had increased mRNA levels of both IL-23 and IL-23R in plasmacytoid dendritic cells, but not in peripheral blood mononuclear cells. (4) IL-23 increased IL-17 release in monocytes and particularly in peripheral blood mononuclear cells from patients with carotid atherosclerosis, but not in cells from healthy controls. (5) IL-23 gave a prominent tumor necrosis factor release in monocytes from patients with carotid atherosclerosis but not in cells from healthy controls. (6) High plasma levels of IL-23 were associated with increased mortality during follow-up. CONCLUSIONS We have shown an association between IL-23 and disease progression in patients with carotid atherosclerosis, potentially involving IL-17-related mechanisms.
Collapse
Affiliation(s)
- Azhar Abbas
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Ida Gregersen
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Sverre Holm
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Isabelle Daissormont
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Vigdis Bjerkeli
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Kirsten Krohg-Sørensen
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Karolina R Skagen
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Tuva B Dahl
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - David Russell
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Trine Almås
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Dorte Bundgaard
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Lars Holger Alteheld
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Azita Rashidi
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Christen P Dahl
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Annika E Michelsen
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Erik A Biessen
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Pål Aukrust
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| | - Bente Halvorsen
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.).
| | - Mona Skjelland
- From the Research Institute of Internal Medicine (A.A., I.G., S.H., V.B., T.B.D., A.R., C.P.D., A.E.M., P.A., B.H.), Department of Neurology (A.A., K.R.S., D.R., M.S.), Department of Thoracic and Cardiovascular Surgery (K.K.-S.), Department of Cardiology (C.P.D.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital Rikshospitalet Oslo, Norway; Department of Neurology, Oslo University Hospital, Ullevål, Norway (L.H.A.); Institute of Clinical Medicine (A.A., I.G., V.B., K.K.-S., T.B.D., D.R., A.E.M., P.A., B.H.), K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (C.P.D.), K.G. Jebsen Inflammation Research Centre (P.A., B.H.), University of Oslo, Oslo, Norway; Department of Neurology (T.A.), Department of Thoracic and Cardiovascular Surgery (D.B.), Østfold Hospital Trust, Fredrikstad, Norway; and Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands (I.D., E.A.B.)
| |
Collapse
|
7
|
Hanssen NMJ, Brouwers O, Gijbels MJ, Wouters K, Wijnands E, Cleutjens JPM, De Mey JG, Miyata T, Biessen EA, Stehouwer CDA, Schalkwijk CG. Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes. Cardiovasc Res 2014; 104:160-70. [PMID: 25139743 DOI: 10.1093/cvr/cvu189] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
AIMS Advanced glycation end-products (AGEs) and their precursors have been associated with the development of atherosclerosis. We recently discovered that glyoxalase 1 (GLO1), the major detoxifying enzyme for AGE precursors, is decreased in ruptured human plaques, and that levels of AGEs are higher in rupture-prone plaques. We here investigated whether overexpression of human GLO1 in ApoE(-/-) mice could reduce the development of atherosclerosis. METHODS AND RESULTS We crossed C57BL/6 ApoE(-/-) mice with C57BL/6 GLO1 overexpressing mice (huGLO1(+/-)) to generate ApoE(-/-) (n = 16) and ApoE(-/-) huGLO1(+/-) (n = 20) mice. To induce diabetes, we injected a subset with streptozotocin (STZ) to generate diabetic ApoE(-/-) (n = 8) and ApoE(-/-) huGLO1(+/-) (n = 13) mice. All mice were fed chow and sacrificed at 25 weeks of age. The GLO1 activity was three-fold increased in huGLO1(+/-) aorta, but aortic root lesion size and phenotype did not differ between mice with and without huGLO1(+/-) overexpression. We detected no differences in gene expression in aortic arches, in AGE levels and cytokines, in circulating cells, and endothelial function between ApoE(-/-) mice with and without huGLO1(+/-) overexpression. Although diabetic mice showed decreased GLO1 expression (P < 0.05) and increased lesion size (P < 0.05) in comparison with non-diabetic mice, GLO1 overexpression also did not affect the aortic root lesion size or inflammation in diabetic mice. CONCLUSION In ApoE(-/-) mice with or without diabetes, GLO1 overexpression did not lead to decreased atherosclerotic lesion size or systemic inflammation. Increasing GLO1 levels does not seem to be an effective strategy to reduce glycation in atherosclerotic lesions, likely due to increased AGE formation through GLO1-independent mechanisms.
Collapse
MESH Headings
- Animals
- Aorta, Thoracic/enzymology
- Aorta, Thoracic/pathology
- Aorta, Thoracic/physiopathology
- Aortic Diseases/blood
- Aortic Diseases/enzymology
- Aortic Diseases/genetics
- Aortic Diseases/pathology
- Aortic Diseases/physiopathology
- Apolipoproteins E
- Atherosclerosis/blood
- Atherosclerosis/enzymology
- Atherosclerosis/genetics
- Atherosclerosis/pathology
- Atherosclerosis/physiopathology
- Cells, Cultured
- Cytokines/blood
- Cytokines/genetics
- Diabetes Mellitus, Experimental/blood
- Diabetes Mellitus, Experimental/chemically induced
- Diabetes Mellitus, Experimental/enzymology
- Diabetes Mellitus, Experimental/genetics
- Diabetes Mellitus, Experimental/pathology
- Diabetes Mellitus, Experimental/physiopathology
- Endothelium, Vascular/enzymology
- Endothelium, Vascular/physiopathology
- Glycation End Products, Advanced/blood
- Humans
- Inflammation Mediators/blood
- Lactoylglutathione Lyase/genetics
- Lactoylglutathione Lyase/metabolism
- Lipoproteins, LDL/metabolism
- Macrophages/enzymology
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- Oxidative Stress
- Plaque, Atherosclerotic
- RNA, Messenger/metabolism
- Severity of Illness Index
- Streptozocin
- Up-Regulation
Collapse
Affiliation(s)
- Nordin M J Hanssen
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, MUMC, Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands
| | - Olaf Brouwers
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, MUMC, Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands
| | - Marion J Gijbels
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Pathology, MUMC, Maastricht, The Netherlands Department of Molecular Genetics, MUMC, Maastricht, The Netherlands Department of Medical Biochemistry, Amsterdam Medical Centre, Amsterdam, The Netherlands
| | - Kristiaan Wouters
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, MUMC, Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands
| | - Erwin Wijnands
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Pathology, MUMC, Maastricht, The Netherlands
| | - Jack P M Cleutjens
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Pathology, MUMC, Maastricht, The Netherlands
| | - Jo G De Mey
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark
| | - Toshio Miyata
- United Centers for Advanced Research and Translational Medicine (ART), Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Erik A Biessen
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Pathology, MUMC, Maastricht, The Netherlands
| | - Coen D A Stehouwer
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, MUMC, Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands
| | - Casper G Schalkwijk
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, MUMC, Debeyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands
| |
Collapse
|
8
|
Lagraauw HM, Westra MM, Bot M, Wezel A, Santbrink PJ, Pasterkamp G, Biessen EA, Kuiper J, Bot I. Abstract 459: Vascular Neuropeptide Y Contributes to Atherosclerotic Plaque Progression and Perivascular Mast Cell Activation. Arterioscler Thromb Vasc Biol 2014. [DOI: 10.1161/atvb.34.suppl_1.459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aim:
Neuropeptide Y is an abundantly expressed neurotransmitter capable of modulating both immune and metabolic responses related to the development of atherosclerosis. NPY receptors are expressed by a number of vascular wall cell types, among which mast cells. However, the direct effects of NPY on perivascular inflammation and atherosclerotic plaque progression remain to be investigated. In this study we thus aimed to determine whether NPY is expressed in atherosclerotic plaques and to establish its role in atherosclerotic plaque development.
Methods and Results:
NPY expression was seen to be increased up to 2-fold in unstable human endarterectomy plaques, as compared to stable plaques (p<0.05, n=9-12), and to be significantly upregulated during lesion progression in apoE
-/-
mice (p<0.001, n=4 per timepoint). In apoE
-/-
mice overexpression of NPY in the carotid artery by means of local application of a lentiviral vector significantly increased atherosclerotic plaque size compared to controls (54 ± 9 *10
3
μm
2
versus 31 ± 6 *10
3
μm
2
, P<0.05, n=12), while plaque composition was unaffected. Interestingly, perivascular mast cell activation was significantly higher in the NPY-overexpressing mice (48.1 ± 4.0 % versus 30.2 ± 6.0 %, P<0.05), suggesting that NPY may impact plaque progression in part via mast cell activation. Furthermore, in vitro NPY-induced murine mast cell activation resulted in the release of pro-atherogenic mediators including IL-6 (515.0 ± 12.5 pg/ml vs. 87.5 ± 5.0 pg/ml) and tryptase.
Conclusions:
Our data show that NPY expression is increased during atherogenesis and in particular in unstable plaques. Furthermore, perivascular overexpression of NPY promoted plaque development and perivascular mast cell activation, suggestive of a role for NPY-induced mast cell activation in lesion progression.
Collapse
Affiliation(s)
- H Maxime Lagraauw
- Biopharmaceutics, Leiden Academic Cntr for Drug Rsch, Leiden, Netherlands
| | - Marijke M Westra
- Biopharmaceutics, Leiden Academic Cntr for Drug Rsch, Leiden, Netherlands
| | - Martine Bot
- Biopharmaceutics, Leiden Academic Cntr for Drug Rsch, Leiden, Netherlands
| | - Anouk Wezel
- Vascular Surgery, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Peter J Santbrink
- Biopharmaceutics, Leiden Academic Cntr for Drug Rsch, Leiden, Netherlands
| | - Gerard Pasterkamp
- Laboratory of Experimental Cardiology, Univ Med Cntr Utrecht, Ultrect, Netherlands
| | - Erik A Biessen
- Experimental Vascular Pathology group, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | - Johan Kuiper
- Biopharmaceutics, Leiden Academic Cntr for Drug Rsch, Leiden, Netherlands
| | - Ilze Bot
- Biopharmaceutics, Leiden Academic Cntr for Drug Rsch, Leiden, Netherlands
| |
Collapse
|
9
|
Halvorsen B, Smedbakken LM, Michelsen AE, Skjelland M, Bjerkeli V, Sagen EL, Taskén K, Bendz B, Gullestad L, Holm S, Biessen EA, Aukrust P. Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. Atherosclerosis 2014; 234:352-9. [PMID: 24732574 DOI: 10.1016/j.atherosclerosis.2014.03.021] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Revised: 02/27/2014] [Accepted: 03/18/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND We have previously shown that the homeostatic chemokine CXCL13 is up-regulated in monocytes in atherosclerosis, mediating anti-apoptotic and anti-inflammatory effects. OBJECTIVE To investigate the regulation of CXCL13s receptor, CXCR5. METHODS/PATIENTS In vitro studies in THP-1 and primary monocytes and studies of CXCR5 expression in thrombus material obtained at the site of plaque rupture during myocardial infarction (MI). RESULTS Our major findings were: (i) toll-like receptor agonists and particularly β-adrenergic receptor activation and releasate from thrombin-activated platelets increased CXCR5 mRNA levels in monocytes. (ii) The platelet-mediated induction of CXCR5 involved prostaglandin E2/cAMP/protein kinase A-dependent as well as RANTES-dependent pathways with NFκB activation as a potential common down-stream mediator. (iii) Releasate from thrombin-activated platelets augmented the anti-inflammatory effects of CXCL13 in monocytes at least partly by enhancing the effects of CXCL13 on CXCR5 expression. (iv) We found strong immunostaining of CXCR5 in thrombus material obtained at the site of plaque rupture in patients with ST elevation MI (STEMI) and in unstable carotid lesions, co-localized with platelets. CONCLUSION Our findings suggest that platelet-mediated signaling through CXCR5 may be active in vivo during plaque destabilization, potentially representing a counteracting mechanism to inflammation.
Collapse
Affiliation(s)
- Bente Halvorsen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
| | - Linda M Smedbakken
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Annika E Michelsen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Mona Skjelland
- Department of Neurology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Vigdis Bjerkeli
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Ellen Lund Sagen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Kjetil Taskén
- Department of Infectious Diseases, Oslo University Hospital Ullevål, Oslo, Norway; Centre for Molecular Medicine Norway, Nordic EMBL Partnership and Biotechnology Centre, Oslo University Hospital and University of Oslo, Oslo, Norway; Biotechnology Centre, University of Oslo, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway
| | - Bjørn Bendz
- Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Lars Gullestad
- Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Sverre Holm
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - Erik A Biessen
- Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands
| | - Pål Aukrust
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway
| |
Collapse
|
10
|
Halvorsen B, Dahl TB, Smedbakken LM, Singh A, Michelsen AE, Skjelland M, Krohg-Sørensen K, Russell D, Höpken UE, Lipp M, Damås JK, Holm S, Yndestad A, Biessen EA, Aukrust P. Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cells. Cardiovasc Res 2014; 102:148-56. [PMID: 24518141 DOI: 10.1093/cvr/cvu036] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
AIMS The homeostatic chemokines, CCL19 and CCL21 and their receptor CCR7, have recently been linked to atherogenesis. We investigated the expression of CCL19/CCL21/CCR7 in carotid atherosclerosis as well as the ability of these chemokines to modulate lipid accumulation in macrophages and vascular smooth muscle cell (SMC) phenotype. METHODS AND RESULTS Our major findings were: (i) patients with carotid atherosclerosis (n = 158) had increased plasma levels of CCL21, but not of CCL19, compared with controls (n = 20), with particularly high levels in symptomatic (n = 99) when compared with asymptomatic (n = 59) disease. (ii) Carotid plaques showed markedly increased mRNA levels of CCL21 and CCL19 in symptomatic (n = 14) when compared with asymptomatic (n = 7) patients, with CCR7 localized to macrophages and vascular SMC (immunohistochemistry). (iii) In vitro, CCL21, but not CCL19, increased the binding of modified LDL and promoted lipid accumulation in THP-1 macrophages. (iv) CCL19, but not CCL21, increased proliferation and release and activity of matrix metalloproteinase (MMP) 1 in vascular SMC. (v) The differential effects of CCL19 and CCL21 in macrophages and SMC seem to be attributable to divergent signalling pathways, with CCL19-mediated activation of AKT in SMC- and CCL21-mediated activation of extracellular signal-regulated kinase 1/2 in macrophages. CONCLUSION CCL19 and CCL21 are up-regulated in carotid atherosclerosis. The ability of CCL21 to promote lipid accumulation in macrophages and of CCL19 to induce proliferation and MMP-1 expression in vascular SMC could contribute to their pro-atherogenic potential.
Collapse
Affiliation(s)
- Bente Halvorsen
- Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
van der Veer EP, de Bruin RG, Kraaijeveld AO, de Vries MR, Pera T, Segers FM, Trompet S, van Gils JM, Roeten MK, Beckers CM, van Santbrink PJ, Janssen A, van Solingen C, Swildens J, de Boer HC, Bot I, Peters EA, Rousch M, Doop M, Schalij MJ, van der Wal AC, Richard S, van Berkel TJ, Pickering JG, Hiemstra PS, Goumans MJ, Rabelink TJ, de Vries AA, Quax PH, Jukema JW, Biessen EA, van Zonneveld AJ. Abstract 532: The RNA-binding Protein Quaking Critically Regulates Vascular Smooth Muscle Cell Phenotype. Arterioscler Thromb Vasc Biol 2013. [DOI: 10.1161/atvb.33.suppl_1.a532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In response to vascular injury, smooth muscle cells (VSMC) adopt a proliferative, synthetic hypocontractile phenotype. This phenotype switch is deemed instrumental in vascular remodeling in both health and disease. Here, we detail a decisive role for the RNA-binding protein Quaking (QKI) in regulating VSMC plasticity. We identified that the RNA-binding protein Quaking (QKI) is highly expressed by neointimal VSMCs of human coronary restenotic lesions, but not in healthy vessels. In a mouse model of vascular injury, we observed reduced neointima hyperplasia in Qk
v
mice, which have decreased QKI expression. Concordantly, abrogation of QKI attenuated fibroproliferative properties of VSMCs, while potently inducing contractile apparatus protein expression, rendering non-contractile VSMCs with the capacity to contract. We identified that QKI localizes to the spliceosome in proliferative VSMCs, where it interacts with and impacts myocardin (pre)-mRNA metabolism by mediating myocardin exon 2a exclusion. As such, in vitro and in vivo experiments indicate that the modulation of QKI expression directly influences the myocardin_v3 / myocardin_v1 mRNA balance, which could play a role in shifting the Myocardin-induced transcriptional coactivation profile following arterial damage. We propose that QKI is a central regulator of VSMC phenotypic plasticity and that intervention in QKI activity can ameliorate pathogenic, fibroproliferative responses to vascular injury.
Collapse
Affiliation(s)
| | | | | | | | - Tonio Pera
- Dept of Pulmonology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Filip M Segers
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | - Stella Trompet
- Dept of Cardiology, Leiden Univ Med Cntr, Leiden, Netherlands
| | | | - Marko K Roeten
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Cora M Beckers
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | | | - Anique Janssen
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | | | - Jim Swildens
- Dept of Cardiology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Hetty C de Boer
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Ilze Bot
- Leiden/Amsterdam Cntr for Drug Rsch, Leiden Univ, Leiden, Netherlands
| | - Erna A Peters
- Dept of Vascular Surgery, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Mat Rousch
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | - Merijn Doop
- Leiden/Amsterdam Cntr for Drug Rsch, Leiden Univ, Leiden, Netherlands
| | | | | | - Stehpane Richard
- Lady Davis Institute for Med Rsch, McGill Univ, Montreal, Canada
| | - Theo J van Berkel
- Leiden/Amsterdam Cntr for Drug Rsch, Leiden Univ, Leiden, Netherlands
| | - J. G Pickering
- Dept of Regenerative Medicine, Univ of Western Ontario, London, Canada
| | | | - Marie Jose Goumans
- Dept of Molecular and Cellular Biology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Ton J Rabelink
- Dept of Nephrology, Leiden Univ Med Cntr, Leiden, Netherlands
| | | | - Paul H Quax
- Dept of Vascular Surgery, Leiden Univ Med Cntr, Leiden, Netherlands
| | - J. W Jukema
- Dept of Cardiology, Leiden Univ Med Cntr, Leiden, Netherlands
| | - Erik A Biessen
- Dept of Pathology, Maastricht Univ Med Cntr, Maastricht, Netherlands
| | | |
Collapse
|
12
|
Smedbakken LM, Halvorsen B, Daissormont I, Ranheim T, Michelsen AE, Skjelland M, Sagen EL, Folkersen L, Krohg-Sørensen K, Russell D, Holm S, Ueland T, Fevang B, Hedin U, Yndestad A, Gullestad L, Hansson GK, Biessen EA, Aukrust P. Increased levels of the homeostatic chemokine CXCL13 in human atherosclerosis – Potential role in plaque stabilization. Atherosclerosis 2012; 224:266-73. [DOI: 10.1016/j.atherosclerosis.2012.06.071] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Revised: 06/15/2012] [Accepted: 06/29/2012] [Indexed: 01/20/2023]
|
13
|
den Dekker WK, Tempel D, Bot I, Biessen EA, Joosten LA, Netea MG, van der Meer JWM, Cheng C, Duckers HJ. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol 2012; 32:1960-9. [PMID: 22652603 DOI: 10.1161/atvbaha.112.250605] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Activated mast cells (MCs) release chymase, which can induce vascular smooth muscle cell (VSMC) apoptosis leading to plaque destabilization. Because the mechanism through which MCs release chymase in atherosclerosis is unknown, we studied whether MC-associated VSMC apoptosis is regulated by toll-like receptor 4 (TLR4) signaling. METHODS AND RESULTS Local recruitment and activation of MCs reduced VSMC content specifically in the cap region of vulnerable plaques in apolipoprotein E knockout mice. Cotreatment with the TLR4 antagonist Bartonella quintana lipopolysaccharide prevented this VSMC loss, suggesting an important role for TLR4 signaling in MC-induced VSMC apoptosis. Coculture of VSMCs with MCs activated by the TLR4 agonist Escherichia coli lipopolysaccharide increased VSMC apoptosis. Apoptosis was inhibited by TLR4 and chymase blockers, indicating that TLR4 signaling is involved in chymase release in MCs. This pathway was mediated via interleukin-6 because interleukin-6 promoted MC-associated VSMC apoptosis, which was inhibited by blocking chymase release. In addition, TLR4 activation in MCs induced interleukin-6 production, which was reduced by preincubation with either B. quintana lipopolysaccharide or an anti-TLR4 antibody. CONCLUSIONS We show that MCs promote VSMC apoptosis in vivo. In addition, TLR4 signaling is important in chymase release in MCs and, therefore, in plaque destabilization by regulating VSMC apoptosis.
Collapse
Affiliation(s)
- Wijnand K den Dekker
- Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Lappalainen JP, Theelen T, Verheyen F, Biessen EA, Aavik E, Anisimov A, Alitalo K, Daemen MJ, Sluimer JC, Ylä-Herttuala S. Abstract 532: Periadventitial Adenoviral Ang-1/2 Gene Transfer Interferes with Atherosclerotic Plaque Progression and Angiogenesis in the Carotid Artery of LDLr
-/-
ApoB100/100 Mice. Arterioscler Thromb Vasc Biol 2012. [DOI: 10.1161/atvb.32.suppl_1.a532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Accumulation of macrophages, red blood cells and lipids in atherosclerotic plaques is associated with plaque rupture. It has been shown that macrophages and erythrocytes can enter the plaque also via plaque microvasculature originating from the adventitia. Furthermore, it has been reported that in advanced or ruptured human coronary lesions the microvessel density is increased and these microvessels are leaky. The leaky phenotype is characterized by poor pericyte coverage and dysfunctional inter-endothelial junctions.
As angiopoietins are involved in angiogenic growth and maturation, we hypothesized that periadventitial Ang-1 or Ang-2 gene transfer would reduce atherogenesis and affect microvasculature in mouse carotid artery.
To study this, atherosclerosis was induced by placing a perivascular silastic collar around the carotid artery of LDLr
-/-
ApoB100/100 mice fed a high cholesterol (0,15 %) diet for 3 weeks. Simultaneous to surgery adenoviral gene transfer (5μl, 5 x 107 pfu/ml) of either Ang-1, Ang-2 or LacZ as a control was applied to the carotid artery (20 mice per group). After 1 or 5 weeks follow-up on high cholesterol diet mice were sacrificed. Plaque size and microvessel density were analyzed with morphometry software (Leica Qwin) using cross-sections stained with hematoxylin and eosin or CD31 respectively. Microvessel ultrastructure was studied using electron microscopy.
Ang-2 gene transfer led to significantly smaller plaque area and plaque volume 5 weeks after collar placement compared to LacZ group (2,7 fold, p<0,001 and 3,9 fold, p<0,01 respectively). Also the microvessel density in intima, media and adventitia was lower in the Ang-2 group compared to LacZ (4,5 fold, p<0,05; 7,5 fold p<0,05 and 11,8 fold p<0,05 respectively). Ang-1 gene transfer led to a non-significant trend towards smaller lesions and lower microvessel density compared to LacZ gene transfer. Plaque phenotype was quite fibrous in all groups at 5 weeks, although lesions in Ang-2 group were most human atheroma-like. Electron microscopy showed intact pericyte coverage and endothelial junctions of microvessels in all groups. Endothelial cell morphology after Ang-1 gene transfer showed less filopodia and cytoplasmic vacuoles compared to Ang-2 and LacZ, suggestive of a quiescent phenotype.
In conclusion:
Ang-2 over expression in mouse carotid arteries led to smaller plaque size and lower microvessel density, suggesting the involvement of angiopoietin signaling in angiogenesis of the atherosclerotic vessel wall.
Collapse
Affiliation(s)
| | | | - Fons Verheyen
- Molecular Cell Biology, Maastricht Univ, Maastricht, Netherlands
| | | | | | | | - Kari Alitalo
- Molecular Cancer Biology, Univ of Helsinki, Helsinki, Finland
| | - Mat J Daemen
- Pathology, Univ of Amsterdam, Amsterdam, Netherlands
| | | | | |
Collapse
|
15
|
Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix ICA, Wijnands E, Goossens P, van Kruchten R, Thevissen L, Boon L, Flavell RA, Noelle RJ, Gerdes N, Biessen EA, Daemen MJAP, Heemskerk JWM, Weber C, Lutgens E. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010. [PMID: 20705757 DOI: 10.1182/blood-2010-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2023] Open
Abstract
CD40 ligand (CD40L), identified as a costimulatory molecule expressed on T cells, is also expressed and functional on platelets. We investigated the thrombotic and inflammatory contributions of platelet CD40L in atherosclerosis. Although CD40L-deficient (Cd40l(-/-)) platelets exhibited impaired platelet aggregation and thrombus stability, the effects of platelet CD40L on inflammatory processes in atherosclerosis were more remarkable. Repeated injections of activated Cd40l(-/-) platelets into Apoe(-/-) mice strongly decreased both platelet and leukocyte adhesion to the endothelium and decreased plasma CCL2 levels compared with wild-type platelets. Moreover, Cd40l(-/-) platelets failed to form proinflammatory platelet-leukocyte aggregates. Expression of CD40L on platelets was required for platelet-induced atherosclerosis as injection of Cd40l(-/-) platelets in contrast to Cd40l(+/+) platelets did not promote lesion formation. Remarkably, injection of Cd40l(+/+), but not Cd40l(-/-), platelets transiently decreased the amount of regulatory T cells (Tregs) in blood and spleen. Depletion of Tregs in mice injected with activated Cd40l(-/-) platelets abrogated the athero-protective effect, indicating that CD40L on platelets mediates the reduction of Tregs leading to accelerated atherosclerosis. We conclude that platelet CD40L plays a pivotal role in atherosclerosis, not only by affecting platelet-platelet interactions but especially by activating leukocytes, thereby increasing platelet-leukocyte and leukocyte-endothelium interactions.
Collapse
Affiliation(s)
- Dirk Lievens
- Department of Pathology, Maastricht Center for Atherosclerosis Research, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, Seijkens T, Engel D, Cleutjens J, Keller AM, Naik SH, Boon L, Oufella HA, Mallat Z, Ahonen CL, Noelle RJ, de Winther MP, Daemen MJ, Biessen EA, Weber C. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. ACTA ACUST UNITED AC 2010; 207:391-404. [PMID: 20100871 PMCID: PMC2822598 DOI: 10.1084/jem.20091293] [Citation(s) in RCA: 199] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The CD40–CD40 ligand (CD40L) signaling axis plays an important role in immunological pathways. Consequently, this dyad is involved in chronic inflammatory diseases, including atherosclerosis. Inhibition of CD40L in apolipoprotein E (Apoe)–deficient (Apoe−/−) mice not only reduced atherosclerosis but also conferred a clinically favorable plaque phenotype that was low in inflammation and high in fibrosis. Blockade of CD40L may not be therapeutically feasible, as long-term inhibition will compromise systemic immune responses. Conceivably, more targeted intervention strategies in CD40 signaling will have less deleterious side effects. We report that deficiency in hematopoietic CD40 reduces atherosclerosis and induces features of plaque stability. To elucidate the role of CD40–tumor necrosis factor receptor-associated factor (TRAF) signaling in atherosclerosis, we examined disease progression in mice deficient in CD40 and its associated signaling intermediates. Absence of CD40-TRAF6 but not CD40-TRAF2/3/5 signaling abolishes atherosclerosis and confers plaque fibrosis in Apoe−/− mice. Mice with defective CD40-TRAF6 signaling display a reduced blood count of Ly6Chigh monocytes, an impaired recruitment of Ly6C+ monocytes to the arterial wall, and polarization of macrophages toward an antiinflammatory regulatory M2 signature. These data unveil a role for CD40–TRAF6, but not CD40–TRAF2/3/5, interactions in atherosclerosis and establish that targeting specific components of the CD40–CD40L pathway harbors the potential to achieve therapeutic effects in atherosclerosis.
Collapse
Affiliation(s)
- Esther Lutgens
- Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht 6200 MD, Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, Weber C. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2007; 102:209-17. [PMID: 17991882 DOI: 10.1161/circresaha.107.160697] [Citation(s) in RCA: 304] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The CXC ligand (CXCL)12/CXC receptor (CXCR)4 chemokine-receptor axis controls hematopoiesis, organ development, and angiogenesis, but its role in the inflammatory pathogenesis of atherosclerosis is unknown. Here we show that interference with Cxcl12/Cxcr4 by a small-molecule antagonist, genetic Cxcr4 deficiency, or lentiviral transduction with Cxcr4 degrakine in bone marrow chimeras aggravated diet-induced atherosclerosis in apolipoprotein E-deficient (Apoe-/-) or LDL receptor-deficient (Ldlr-/-) mice. Chronic blockade of Cxcr4 caused leukocytosis and an expansion of neutrophils and increased neutrophil content in plaques, associated with apoptosis and a proinflammatory phenotype. Whereas circulating neutrophils were recruited to atherosclerotic lesions, depletion of neutrophils reduced plaque formation and prevented its exacerbation after blocking Cxcr4. Disrupting Cxcl12/Cxcr4 thus promotes lesion formation through deranged neutrophil homeostasis, indicating that Cxcl12/Cxcr4 controls the important contribution of neutrophils to atherogenesis in mice.
Collapse
Affiliation(s)
- Alma Zernecke
- Institute for Molecular Cardiovascular Research, Rheinisch-Westfälische Technische Hochschule, Aachen University, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, van Santbrink PJ, Nelson PJ, Biessen EA, Mertens PR, Weber C. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 2007; 116:1812-20. [PMID: 17893273 DOI: 10.1161/circulationaha.107.708016] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The CC chemokine CCL5/Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) is upregulated in mononuclear cells or deposited by activated platelets during inflammation and has been implicated in atherosclerosis and neointimal hyperplasia. We investigated the influence of the transcriptional regulator Y-box binding protein (YB)-1 on CCL5 expression and wire-induced neointimal hyperplasia. METHODS AND RESULTS Analysis of the CCL5 promoter revealed potential binding sites for YB-1, and interaction of YB-1 with a sequence at position -204/-173 was confirmed by DNA binding assays. Both YB-1 expression and CC chemokine ligand-5 (CCL5) mRNA expression were increased in neointimal versus medial smooth muscle cells, as analyzed by real-time polymerase chain reaction. Overexpression of YB-1 in smooth muscle cells (but not macrophages) enhanced CCL5 transcriptional activity in reporter assays, mRNA and protein expression, and CCL5-mediated monocyte arrest. Carotid arteries of hyperlipidemic apolipoprotein E-deficient mice were subjected to intraluminal transfection with a lentivirus encoding YB-1 short hairpin RNA or empty vector directly after wire injury. Double immunofluorescence revealed YB-1 expression in neointimal smooth muscle cells but not macrophages and colocalization with neointimal CCL5, which was downregulated by YB-1 short hairpin RNA. Neointima formation was decreased significantly after YB-1 knockdown compared with controls and was associated with a diminished content of lesional macrophages. A reduction of lesion formation by YB-1 knockdown was not observed in apolipoprotein E-deficient mice deficient in the CCL5 receptor CCR5 or after treatment with the CCL5 antagonist Met-RANTES, which indicates that YB-1 effects were dependent on CCL5. CONCLUSIONS The transcriptional regulator YB-1 mediates CCL5 expression in smooth muscle cells and thereby contributes to neointimal hyperplasia, thus representing a novel target with which to limit vascular remodeling.
Collapse
MESH Headings
- Animals
- Apolipoproteins E/genetics
- Atherosclerosis/metabolism
- Atherosclerosis/pathology
- Atherosclerosis/physiopathology
- Cell Line
- Chemokine CCL5/antagonists & inhibitors
- Chemokine CCL5/genetics
- Chemokine CCL5/metabolism
- Chemokine CCL5/pharmacology
- Coronary Vessels/cytology
- Macrophages/cytology
- Macrophages/physiology
- Mice
- Mice, Knockout
- Monocytes/cytology
- Monocytes/physiology
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/pathology
- Muscle, Smooth, Vascular/physiology
- Promoter Regions, Genetic/physiology
- Rats
- Rats, Sprague-Dawley
- Thoracic Arteries/cytology
- Transcription, Genetic/physiology
- Tunica Intima/pathology
- Y-Box-Binding Protein 1/genetics
- Y-Box-Binding Protein 1/metabolism
Collapse
Affiliation(s)
- Regina Krohn
- Institute for Molecular Cardiovascular Research, University Hospital Aachen, RWTH Aachen University, Aachen, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
de Boer HC, Verseyden C, Ulfman LH, Zwaginga JJ, Bot I, Biessen EA, Rabelink TJ, van Zonneveld AJ. Fibrin and Activated Platelets Cooperatively Guide Stem Cells to a Vascular Injury and Promote Differentiation Towards an Endothelial Cell Phenotype. Arterioscler Thromb Vasc Biol 2006; 26:1653-9. [PMID: 16627804 DOI: 10.1161/01.atv.0000222982.55731.f1] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Bone marrow-derived progenitor cells play a role in vascular regeneration. However, their homing to areas of vascular injury is poorly understood. One of the earliest responses to an injury is the activation of coagulation and platelets. In this study we assessed the role of hemostatic components in the recruitment of CD34
+
cells to sites of injury.
Methods and Results—
Using an ex vivo injury model, representing endothelial cell (EC) injury or vessel denudation, we studied homing of CD34
+
under flow. Platelet aggregates facilitated initial tethering and rolling of CD34
+
cells through interaction of P-selectin expressed by platelets and P-selectin glycoprotein ligand-1 (PSGL-1), expressed by CD34
+
cells. Ligation of PSGL-1 activated adhesion molecules on CD34
+
cells, ultimately leading to firm adhesion of CD34
+
cells to tissue factor-expressing ECs or to fibrin-containing thrombi formed on subendothelium. We also demonstrate that fibrin-containing thrombi can support migration of CD34
+
cells to the site of injury and subsequent differentiation toward a mature EC phenotype. Additionally, intravenously injected CD34
+
cells homed in vivo to denuded arteries in the presence of endogenous leukocytes.
Conclusions—
We provide evidence that hemostatic factors, associated with vascular injury, provide a regulatory microenvironment for re-endothelialization mediated by circulating progenitor cells.
Collapse
Affiliation(s)
- H C de Boer
- Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Möpps B, Mericskay M, Gierschik P, Biessen EA, Weber C. SDF-1α/CXCR4 Axis Is Instrumental in Neointimal Hyperplasia and Recruitment of Smooth Muscle Progenitor Cells. Circ Res 2005; 96:784-91. [PMID: 15761195 DOI: 10.1161/01.res.0000162100.52009.38] [Citation(s) in RCA: 294] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Recent evidence infers a contribution of smooth muscle cell (SMC) progenitors and stromal cell-derived factor (SDF)-1alpha to neointima formation after arterial injury. Inhibition of plaque area and SMC content in apolipoprotein E-deficient mice repopulated with LacZ+ or CXCR4-/- BM or lentiviral transfer of an antagonist reveals a crucial involvement of local SDF-1alpha and its receptor CXCR4 in neointimal hyperplasia via recruitment of BM-derived SMC progenitors. After arterial injury, SDF-1alpha expression in medial SMCs is preceded by apoptosis and inhibited by blocking caspase-dependent apoptosis. SDF-1alpha binds to platelets at the site of injury, triggers CXCR4- and P-selectin-dependent arrest of progenitor cells on injured arteries or matrix-adherent platelets, preferentially mobilizes and recruits c-kit-/platelet-derived growth factor receptor (PDGFR)-beta+/lineage-/sca-1+ progenitors for neointimal SMCs without being required for their differentiation. Hence, the SDF-1alpha/CXCR4 axis is pivotal for vascular remodeling by recruiting a subset of SMC progenitors in response to apoptosis and in concert with platelets, epitomizing its importance for tissue repair and identifying a prime target to limit lesion development.
Collapse
Affiliation(s)
- Alma Zernecke
- Department of Molecular Cardiovascular Research, University Hospital, Rheinisch-Westfälische Technische Hochschule, Aachen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Halvorsen B, Waehre T, Scholz H, Clausen OP, von der Thüsen JH, Müller F, Heimli H, Tonstad S, Hall C, Frøland SS, Biessen EA, Damås JK, Aukrust P. Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res 2005; 46:211-9. [PMID: 15547296 DOI: 10.1194/jlr.m400324-jlr200] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Interleukin (IL)-10 may have a therapeutic potential in atherosclerosis, but its mechanisms of action have not been clarified. Foam cell formation is a key event in atherogenesis, and apoptosis of these lipid-laden cells may promote plaque destabilization. We sought to explore whether IL-10 could have plaque-stabilizing properties in acute coronary syndromes (ACS). We studied the effect of IL-10 on oxidized low density lipoprotein (oxLDL)-stimulated THP-1 cells and monocyte-derived macrophages from ACS patients and healthy controls using different experimental approaches. Our main findings were: i) IL-10 enhances lipid accumulation in oxLDL-stimulated THP-1 macrophages, at least partly by counteracting oxLDL-induced apoptosis; ii) This antiapoptotic effect of IL-10 involves increased expression of the antiapoptotic genes Bfl-1 and Mcl-1, accompanied by protective effects on mitochondria function; iii) By silencing Bfl-1 and Mcl-1 genes using siRNAs, we were able to abolish this IL-10-mediated effect on lipid accumulation; iv) IL-10 also induced lipid accumulation in oxLDL-stimulated macrophages from patients with ACS, but not in macrophages from healthy controls; v) In ACS patients, this enhancing effect of IL-10 on lipid accumulation was accompanied by enhanced Mcl-1 expression. No such antiapoptotic effect was seen in macrophages from healthy controls. These findings suggest a new mechanism for the effect of IL-10 in atherosclerosis, possibly contributing to plaque stabilization.
Collapse
Affiliation(s)
- Bente Halvorsen
- Research Institute for Internal Medicine, The National Hospital, Oslo, Norway.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Von Der Thüsen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ, Biessen EA. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J 2001; 15:2730-2. [PMID: 11687507 DOI: 10.1096/fj.01-0483fje] [Citation(s) in RCA: 114] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
In view of its multifaceted anti-inflammatory properties, interleukin-10 (IL-10) has been deemed to be potentially anti-atherogenic. We have evaluated the capacity of adenoviral gene transfer of IL-10 for the modulation of de novo atherosclerotic lesion formation by systemic and by local overexpression. Atherogenesis was initiated in the carotid arteries of low-density lipoprotein receptor deficient mice by perivascular placement of silastic collars. One week after collar placement, mice were injected intravenously with 1 x 109 plaque-forming units (pfu's) of IL-10 (AdV.IL-10) or control adenovirus (AdV.empty). Administration of AdV.IL-10 resulted in extended systemic expression of IL-10 (peak serum level 3.0 +/- 1.1 ng/ml) and a reduction in atherosclerotic lumen stenosis by 62.2% (P<0.02). This finding was accompanied by monocyte deactivation and lowering of serum cholesterol levels (maximum decrease 44%). In a second experiment, collared arteries were transfected locally by transluminal instillation of adenovirus (titer 1.5x1010 pfu/ml). Systemic parameters remained unchanged following local transfection, but the degree of stenosis was, nonetheless, decreased by 44.9% (P<0.05). We conclude that a marked inhibition of atherogenesis can be achieved by systemic overexpression of AdV.IL-10, owing to its metabolic and immunomodulatory effects. Local IL-10 transfer is virtually equipotent, however, and it may represent a valuable addition to the armory of anti-atherosclerotic therapies.
Collapse
Affiliation(s)
- J H Von Der Thüsen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, 2300 RA Leiden, The Netherlands
| | | | | | | | | | | |
Collapse
|
23
|
Rensen PC, Sliedregt LA, Ferns M, Kieviet E, van Rossenberg SM, van Leeuwen SH, van Berkel TJ, Biessen EA. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem 2001; 276:37577-84. [PMID: 11479285 DOI: 10.1074/jbc.m101786200] [Citation(s) in RCA: 158] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The asialoglycoprotein receptor (ASGPr) on hepatocytes plays a role in the clearance of desialylated proteins from the serum. Although its sugar preference (N-acetylgalactosamine (GalNAc) >> galactose) and the effects of ligand valency (tetraantennary > triantennary >> diantennary >> monoantennary) and sugar spacing (20 A 10 A 4 A) are well documented, the effect of particle size on recognition and uptake of ligands by the receptor is poorly defined. In the present study, we assessed the maximum ligand size that still allows effective processing by the ASGPr of mouse hepatocytes in vivo and in vitro. Here too, we synthesized a novel glycolipid, which possesses a highly hydrophobic steroid moiety for stable incorporation into liposomes, and a triantennary GalNAc(3)-terminated cluster glycoside with a high nanomolar affinity (2 nm) for the ASGPr. Incorporation of the glycolipid into small (30 nm) [(3)H]cholesteryl oleate-labeled long circulating liposomes (1-50%, w/w) caused a concentration-dependent increase in particle clearance that was liver-specific (reaching 85 +/- 7% of the injected dose at 30 min after injection) and mediated by the ASGPr on hepatocytes, as shown by competition studies with asialoorosomucoid in vivo. By using glycolipid-laden liposomes of various sizes between 30 and 90 nm, it was demonstrated that particles with a diameter of >70 nm could no longer be recognized and processed by the ASGPr in vivo. This threshold size for effective uptake was not related to the physical barrier raised by the fenestrated sinusoidal endothelium, which shields hepatocytes from the circulation, because similar results were obtained by studying the uptake of liposomes on isolated mouse hepatocytes in vitro. From these data we conclude that in addition to the species, valency, and orientation of sugar residues, size is also an important determinant for effective recognition and processing of substrates by the ASGPr. Therefore, these data have important implications for the design of ASGPr-specific carriers that are aimed at hepatocyte-directed delivery of drugs and genes.
Collapse
Affiliation(s)
- P C Rensen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, Sylvius Laboratory, 2300 RA Leiden, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Bijsterbosch MK, Ying C, de Vrueh RL, de Clercq E, Biessen EA, Neyts J, van Berkel TJ. Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus. Mol Pharmacol 2001; 60:521-7. [PMID: 11502883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
We recently synthesized a lipophilic prodrug of 9-(2-phosphonyl-methoxyethyl)adenine (PMEA), designated PMEA-LO, and incorporated it into reconstituted lactosylated high-density lipoprotein (LacNeoHDL). In a rat model, LacNeoHDL-associated PMEA-LO was internalized by the asialoglycoprotein receptor on parenchymal liver cells and converted into its active diphosphorylated metabolite. To further evaluate the therapeutic potential of the carrier-associated prodrug, we examined in this study the processing of (125)I-labeled PMEA-LO--loaded LacNeoHDL by HepG2 cells. Upon incubation with HepG2 cells, PMEA-LO--loaded LacNeoHDL became rapidly cell-associated. The association was saturable and of high-affinity (k(d) = 3.8 +/- 0.4 nM). Asialofetuin, an established ligand for the asialoglycoprotein receptor, inhibited the association by >75%, which confirms the role of the asialoglycoprotein receptor. Association of the prodrug-loaded particles to HepG2 cells was coupled to degradation. Radiolabeled degradation products appeared in the culture medium with a lag phase of 2 h. Asialofetuin and chloroquine inhibited secretion of degradation products by 75 to 80%, indicating that PMEA-LO--loaded LacNeoHDL is internalized via the asialoglycoprotein receptor and lysosomally processed. The therapeutic potential of LacNeoHDL-associated PMEA-LO was studied by measuring its effects on hepatitis B virus (HBV) replication in Hep AD38 cells (HBV-transfected HepG2 cells). LacNeoHDL-associated PMEA-LO effectively inhibited HBV DNA synthesis. The EC(50) value of carrier-associated PMEA-LO was 35 times lower than that of free PMEA (3.4 +/- 0.4 and 120 +/- 18 ng of PMEA/ml, respectively). We conclude that the present results, combined with our earlier in vivo disposition data, underscore the therapeutic potential and utility of PMEA-LO--loaded LacNeoHDL for treatment of chronic hepatitis B.
Collapse
Affiliation(s)
- M K Bijsterbosch
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
25
|
Bijsterbosch MK, Manoharan M, Dorland R, Waarlo IH, Biessen EA, van Berkel TJ. Delivery of cholesteryl-conjugated phosphorothioate oligodeoxynucleotides to Kupffer cells by lactosylated low-density lipoprotein. Biochem Pharmacol 2001; 62:627-33. [PMID: 11585059 DOI: 10.1016/s0006-2952(01)00705-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The efficacy of antisense oligonucleotides depends on the ability to reach in vivo their target cells. We aim to develop strategies to enhance uptake of phosphorothioate oligodeoxynucleotides by Kupffer cells. To this end, we conjugated cholesterol to ISIS-3082, a phosphorothioate oligodeoxynucleotide specific for intercellular adhesion molecule-1. The cholesterol-conjugated oligonucleotide, denoted ISIS-9388, associated readily with lactosylated low-density lipoprotein (LacLDL), a lipidic carrier that is taken up by galactose receptors on Kupffer cells. Association of up to 10 molecules of ISIS-9388 per LacLDL particle did not induce aggregation. LacLDL-associated [3H]ISIS-9388 was rapidly taken up by the liver after injection into rats (52.9+/-1.8% of the dose within 2 min versus 18.6+/-2.8% for ISIS-3082). N-acetylgalactosamine inhibited hepatic uptake, indicating involvement of galactose-specific receptors. Liver cells were isolated at 60 min after injection of LacLDL-associated [3H]ISIS-9388. Kupffer cells displayed the highest uptake: 88.1+/-24.7 ng of oligonucleotide/mg of cell protein, which is 6-14 times higher than after injection of free ISIS-9388 or ISIS-3082 (15.0+/-3.8 ng and 6.3+/-1.4 ng, respectively). It can be calculated that Kupffer cells contribute 43.9+/-5.4% to the liver uptake (free ISIS-9388 and ISIS-3083 14.5+/-3.1% and 8.3+/-3.2%, respectively). In conclusion, conjugation of a phosphorothioate oligodeoxynucleotide with cholesterol and its subsequent association with LacLDL results in a substantially increased Kupffer cell uptake of the oligonucleotide. As Kupffer cells play a key role in inflammation, our approach may be utilized to improve antisense-based therapeutic intervention during inflammation.
Collapse
Affiliation(s)
- M K Bijsterbosch
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, The Netherlands.
| | | | | | | | | | | |
Collapse
|
26
|
Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001; 47:251-76. [PMID: 11311995 DOI: 10.1016/s0169-409x(01)00109-0] [Citation(s) in RCA: 150] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Lipoproteins are endogenous particles that transport lipids through the blood to various cell types, where they are recognised and taken up via specific receptors. These particles are, therefore, excellent candidates for the targeted delivery of drugs to various tissues. For example, the remnant receptor and the asialoglycoprotein receptor (ASGPr), which are uniquely localised on hepatocytes, recognise chylomicrons and lactosylated high density lipopoteins (HDL), respectively. In addition, tumour cells of various origins overexpress the low density lipoprotein (LDL) receptor that recognises apolipoprotein E (apoE) on small triglyceride-rich particles and apoB-100 on LDL. Being endogenous, lipoproteins are biodegradable, do not trigger immune reactions, and are not recognised by the reticuloendothelial system (RES). However, their endogenous nature also hampers large-scale pharmaceutical application. In the past two decades, various research groups have successfully synthesised recombinant lipoproteins from commercially available natural and synthetic lipids and serum-derived or recombinant apolipoproteins, which closely mimic the metabolic behaviour of their native counterparts in animal models as well as humans. In this paper, we will summarise the studies that led to the development of these recombinant lipoproteins, and we will address the possibility of using these lipidic particles to selectively deliver a wide range of lipophilic, amphiphilic, and polyanionic compounds to hepatocytes and tumour cells. In addition, the intrinsic therapeutic activities of recombinant chylomicrons and HDL in sepsis and atherosclerosis will be discussed.
Collapse
Affiliation(s)
- P C Rensen
- Sylvius Laboratories, Amsterdam Center for Drug Research, Division of Biopharmaceutics, Leiden, University of Leiden, P.O. Box 9503, 2300 RA, Leiden, The Netherlands.
| | | | | | | | | | | |
Collapse
|
27
|
van Rossenberg SM, Sliedregt LA, Autar R, Piperi C, Van Der Merwe AP, van Berkel TJ, Kuiper J, Biessen EA. A structure-function study of ligand recognition by CD22beta. J Biol Chem 2001; 276:12967-73. [PMID: 11152460 DOI: 10.1074/jbc.m009276200] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
B-cell-specific CD22 is a member of a group of cell adhesion molecules within the immunoglobulin superfamily that display binding to glycans with terminal sialic acid residues. Binding of endogenous ligands to CD22 triggers B-cell activation and proliferation. It is therefore conceivable that high affinity ligands for CD22 may be of value as inhibitors of B-cell activation in allergy and chronic inflammation. In this study, we aimed to delineate the structural requirements for ligand binding to CD22. A library of 20 mono-, di-, and trisaccharide analogs of the basic binding motif Neu5Ac(alpha2,6)Lac was synthesized and screened for affinity for CD22beta. In general, CD22 ligand recognition appeared to be rather tolerant with respect to structural modifications of the anomeric sugar on a mono-, di-, and trisaccharide level, although affinity was increased by the presence of a nitro aromatic group at C-2. The most potent monovalent ligand, Neu5Ac-4-nitrobenzoyl-Glc, was selected to generate multivalent ligands based on either a glutamate or Tris cluster core. All multivalent ligands displayed at least a 10-fold increased affinity for CD22 compared with the corresponding monovalent glycoside. Interestingly, a maximal gain in affinity was already obtained for bivalent ligands, regardless of the terminal glycoside. A trivalent Tris-based cluster of Neu5Ac-4-nitrobenzoyl-Glc displayed a 300-fold higher affinity compared with the basic binding motif, which makes it, to our knowledge, the most potent antagonist for CD22 yet synthesized. As our in vitro fluorescence-activated cell sorting studies demonstrated efficient cellular uptake of a CD22 substrate, the most potent ligand in this study may hold promise as a homing device for immunomodulatory compounds and cytostatics.
Collapse
Affiliation(s)
- S M van Rossenberg
- Leiden/Amsterdam Center for Drug Research, Division of Biopharmaceutics, Sylvius Laboratories, Leiden University, 2300 RA Leiden, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
von der Thüsen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001; 103:1164-70. [PMID: 11222482 DOI: 10.1161/01.cir.103.8.1164] [Citation(s) in RCA: 163] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Perivascular collar placement has been used as a means for localized atherosclerosis induction in a variety of experimental animal species. In mice, however, atherosclerosis-like lesions have thus far not been obtained by this method. The aim of this study was the development of a mouse model of rapid, site-controlled atherogenesis. METHODS AND RESULTS Silastic collars were placed around the carotid arteries of apolipoprotein E-deficient (apoE-/-) and LDL receptor-deficient (LDLr-/-) mice. The development of collar-induced lesions was found to occur predominantly in the area proximal to the collar and to be dependent on a high-cholesterol diet. Lesions were evident in apoE-/- mice after 3 weeks and in LDLr-/- mice after 6 weeks and were overtly atherosclerotic in appearance. Lumen stenosis reached 85% in apoE-/- mice and 61% in LDLr-/- mice 6 weeks after collar insertion. Expression levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 were increased both proximal and distal to the collar, whereas endothelial nitric oxide synthase expression was downregulated at the proximal site. CONCLUSIONS We propose that this model of collar-induced acceleration of carotid atherogenesis is of hemodynamic cause. It may serve as a substrate for sequential mechanistic studies concerned with the underlying cause and pathogenesis of atherosclerosis. The rapidity of lesion development will also aid the efficient screening of new potentially antiatherogenic chemical entities and the evaluation of therapies with limited duration of effectiveness, such as adenoviral gene therapy.
Collapse
Affiliation(s)
- J H von der Thüsen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, Leiden, The Netherlands.
| | | | | |
Collapse
|
29
|
Sliedregt LA, van Rossenberg SM, Autar R, Valentijn AR, van der Marel GA, van Boom JH, Piperi C, van der Merwe PA, Kuiper J, van Berkel TJ, Biessen EA. Design and synthesis of a multivalent homing device for targeting to murine CD22. Bioorg Med Chem 2001; 9:85-97. [PMID: 11197350 DOI: 10.1016/s0968-0896(00)00224-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
CD22 is a cell-surface glycoprotein uniquely located on mature B-cells and B-cell derived tumour cells. Current evidence suggests that binding of endogenous ligands to CD22 leads to modulation of B-cell activation by antigen. Incidentally, however, B-cell activation may derail. and lead to an undesired immune response, for example in cases of allergy, rheumatoid arthritis and Crohn's disease. In this situation, synthetic high-affinity ligands for CD22 may be of therapeutic value as inhibitors of B-cell activation. Recent studies have revealed that natural ligands for CD22 contain the trisaccharide NeuAc alpha-2,6-Lac as the basic binding motif. In addition, it has been demonstrated that binding to CD22 is strongly enhanced by multivalent presentation of the basic binding motif (cluster effect). In this paper. the stepwise development of a novel multivalent high-affinity ligand for CD22 is described. In the first stage, a series of monovalent NeuAc alpha-2,6-Glc(Y)X type binding motifs was prepared, and their affinity for murine CD22 was monitored, to obtain more insight into the effect of separate structure elements on ligand recognition. In the second stage, we prepared a trivalent cluster, based on the monovalent motif that displayed the highest affinity for CD22, NeuAc alpha-2,6-GlcNBzNO2OMe (7). This cluster, TRIS(NeuAc alpha-2,6-GlcNBzNO2)3 (52), displayed a more than 58-fold higher affinity for CD22 than the reference structure NeuAc alpha-2,6-LacOMe (10). To our knowledge, the cluster 52 is one of the most potent antagonists for CD22 yet synthesised.
Collapse
Affiliation(s)
- L A Sliedregt
- Leiden/Amsterdam Center for Drug Research, Division of Biopharmaceutics, Sylvius Laboratories, Leiden University, The Netherlands
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Rump ET, Biessen EA, van Berkel TJ, Bijsterbosch MK. Interactions of lipid-oligonucleotide conjugates with low-density lipoprotein. Methods Mol Med 2001; 65:89-104. [PMID: 21318747 DOI: 10.1385/1-59259-139-6:89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The ability of antisense oligonucleotides to interdict, sequence-specifically, the expression of pathogenic genes affords an exciting new strategy for therapeutic intervention (1-3). Oligonucleotides with physiological phosphodiester internucleotide bonds are rapidly degraded, predominantly by exonucleases. Numerous oligonucleotide analogs have therefore been synthesized to confer resistance toward nuclease activity (3). The phosphorothioate analog is the most extensively studied, and phosphorothioate oligodeoxynucleotides have been shown to be potent inhibitors of the expression of their target genes in vitro and in vivo (1,3). However, phosphorothioate oligodeoxynucleotides also bind avidly and nonspecifically to proteins, thus provoking a variety of non-antisense effects (4). Oligonucleotide analogs that do not bind to proteins are therefore expected to display less nonantisense side effects. However, protein binding also affects the in vivo disposition of oligonucleotides. Nonphosphorothioate oligonucelotide analogs generally do not bind to serum proteins, and are therefore rapidly cleared from the circulation, protein-bound phosphorothioate oligodeoxynucelotides circulate much longer (5,6).
Collapse
Affiliation(s)
- E T Rump
- Division of Biopharmaceutics, Center for Drug Research, Leiden/Amsterdam, Leiden, Netherlands
| | | | | | | |
Collapse
|
31
|
Joziasse DH, Lee RT, Lee YC, Biessen EA, Schiphorst WE, Koeleman CA, van den Eijnden DH. alpha3-galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor. Eur J Biochem 2000; 267:6501-8. [PMID: 11029595 DOI: 10.1046/j.1432-1327.2000.01747.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In mammals, clearance of desialylated serum glycoproteins to the liver is mediated by a galactose-specific hepatic lectin, the 'asialoglycoprotein receptor'. In humans, serum glycoprotein glycans are usually capped with sialic acid, which protects these proteins against hepatic uptake. However, in most other species, an additional noncharged terminal element with the structure Galalpha1-->3Galbeta1-->4R is present on glycoprotein glycans. To investigate if alpha3-galactosylated glycoproteins, just like desialylated glycoproteins, could be cleared by the hepatic lectin, the affinities of alpha3-galactosylated compounds towards this lectin were determined using an in vitro inhibition assay, and were compared with those of the parent compounds terminating in Galbeta1-->4R. Diantennary, triantennary and tetraantennary oligosaccharides that form part of N-glycans were alpha3-galactosylated to completion by use of recombinant bovine alpha3-galactosyltransferase. Similarly, desialylated alpha1-acid glycoprotein (orosomucoid) was alpha3-galactosylated in vitro. The alpha3-galactosylation of a branched, Galbeta1-->4-terminated oligosaccharide lowered its affinity for the membrane-bound lectin on whole rat hepatocytes 50-250-fold, and for the detergent-solubilized hepatic lectin 7-50-fold. In contrast, alpha3-galactosylation of asialo-alpha1-acid glycoprotein caused only a minor decrease in affinity, increasing the IC50 from 5 to 15 nM. Fully alpha3-galactosylated alpha1-acid glycoprotein, intravenously injected into the mouse, was rapidly cleared from the circulation, with a clearance rate close to that of asialo-alpha1-acid glycoprotein (t1/2 of 0.42 min vs. 0.95 min). Its uptake was efficiently inhibited by pre-injection of an excess asialo-fetuin. Organ distribution analysis showed that the injected alpha1-acid glycoprotein accumulated predominantly in the liver. Taken together, these observations suggest that serum glycoproteins that are heavily alpha3-galactosylated will be rapidly cleared from the bloodstream via the hepatic lectin. It is suggested that glycosyltransferase expression in murine hepatocytes is tightly regulated in order to prevent undesired uptake of hepatocyte-derived, circulating glycoproteins.
Collapse
Affiliation(s)
- D H Joziasse
- Department of Medical Chemistry, Vrije Universiteit, Amsterdam, the Netherlands.
| | | | | | | | | | | | | |
Collapse
|
32
|
Biessen EA, Valentijn AR, De Vrueh RL, Van De Bilt E, Sliedregt LA, Prince P, Bijsterbosch MK, Van Boom JH, Van Der Marel GA, Abrahams PJ, Van Berkel TJ. Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity. FASEB J 2000; 14:1784-92. [PMID: 10973928 DOI: 10.1096/fj.99-0887com] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The device of new hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine (PMEA) with specificity for the asialoglycoprotein receptor on parenchymal liver cells is described. PMEA was conjugated to bi- and trivalent cluster glycosides (K(GN)(2) and K(2)(GN)(3), respectively) with nanomolar affinity for the asialoglycoprotein receptor. The liver uptake of the PMEA prodrugs was more than 10-fold higher than that of the parent drug (52+/-6% and 62+/-3% vs. 4.8+/-0.7% of the injected dose for PMEA) and could be attributed for 90% to parenchymal cells. Accumulation of the PMEA prodrugs in extrahepatic tissue (e.g., kidney, skin) was substantially reduced. The ratio of parenchymal liver cell-to-kidney uptake-a measure of the prodrugs therapeutic window-was increased from 0.058 +/- 0.01 for PMEA to 1.86 +/- 0.57 for K(GN)(2)-PMEA and even 2.69 +/- 0.24 for K(2)(GN)(3)-PMEA. Apparently both glycosides have a similar capacity to redirect (antiviral) drugs to the liver. After cellular uptake, both PMEA prodrugs were converted into the parent drug, PMEA, during acidification of the lysosomal milieu (t(1/2) approximately 100 min), and the released PMEA was rapidly translocated into the cytosol. The antiviral activity of the prodrugs in vitro was dramatically enhanced as compared to the parent drug (5- and 52-fold for K(GN)(2)-PMEA and K(2)(GN)(3)-PMEA, respectively). Given the 15-fold enhanced liver uptake of the prodrugs, we anticipate that the potency in vivo will be similarly increased. We conclude that PMEA prodrugs have been developed with greatly improved pharmacokinetics and therapeutic activity against viral infections that implicate the liver parenchyma (e.g., HBV). In addition, the significance of the above prodrug concept also extends to drugs that intervene in other liver disorders such as cholestasis and dyslipidemia.
Collapse
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, LACDR, Department of Bio-Organic Chemistry, LIC, Leiden University, Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Bijsterbosch MK, Rump ET, De Vrueh RL, Dorland R, van Veghel R, Tivel KL, Biessen EA, van Berkel TJ, Manoharan M. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res 2000; 28:2717-25. [PMID: 10908328 PMCID: PMC102653 DOI: 10.1093/nar/28.14.2717] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2000] [Revised: 05/26/2000] [Accepted: 05/26/2000] [Indexed: 01/13/2023] Open
Abstract
Several studies have shown improved efficacy of cholesteryl-conjugated phosphorothioate antisense oligodeoxynucleotides. To gain insight into the mechanisms of the improved efficacy in vivo, we investigated the disposition of ISIS-9388, the 3'-cholesterol analog of the ICAM-1-specific phosphorothioate oligodeoxynucleotide ISIS-3082, in rats. Intravenously injected [(3)H]ISIS-9388 was cleared from the circulation with a half-life of 49.9 +/- 2.2 min (ISIS-3082, 23.3 +/- 3.8 min). At 3 h after injection, the liver contained 63.7 +/- 3. 3% of the dose. Compared to ISIS-3082, the hepatic uptake of ISIS-9388 is approximately 2-fold higher. Endothelial, Kupffer and parenchymal cells accounted for 45.7 +/- 5.7, 33.0 +/- 5.9 and 21.3 +/- 2.6% of the liver uptake of [(3)H]ISIS-9388, respectively, and intracellular concentrations of approximately 2, 75 and 50 microM, respectively, could be reached in these cells (1 mg/kg dose). Preinjection with polyinosinic acid or poly-adenylic acid reduced the hepatic uptake of [(3)H]ISIS-9388, which suggests the involvement of (multiple) scavenger receptors. Size exclusion chromatography of mixtures of the oligonucleotides and rat plasma indicated that ISIS-9388 binds to a larger extent to high molecular weight proteins than ISIS-3082. Analysis by agarose gel electrophoresis indicated that ISIS-9388 binds more tightly to plasma proteins than ISIS-3082. The different interaction of the oligonucleotides with plasma proteins possibly explains their different dispositions. We conclude that cholesterol conjugation results in high accumulation of phosphorothioate oligodeoxynucleotides in various liver cell types, which is likely to be beneficial for antisense therapy of liver-associated diseases.
Collapse
Affiliation(s)
- M K Bijsterbosch
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, PO Box 9503, 2300 RA Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Rump ET, de Vrueh RL, Manoharan M, Waarlo IH, van Veghel R, Biessen EA, van Berkel TJ, Bijsterbosch MK. Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein. Biochem Pharmacol 2000; 59:1407-16. [PMID: 10751550 DOI: 10.1016/s0006-2952(00)00243-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Low-density lipoprotein (LDL) has been proposed as carrier for the selective delivery of anticancer drugs to tumor cells. We reported earlier the association of several lipidic steroid-conjugated anticancer oligodeoxynucleotides (ODNs) with LDL. In the present study, we determined the stability of these complexes. When the complexes were incubated with a mixture of high-density lipoprotein and albumin, or with rat plasma, the oleoyl steroid-conjugated ODNs appeared to be more stably associated with LDL than the cholesteryl-conjugated ODN. Intravenously injected free lipid-ODNs were very rapidly cleared from the circulation of rats. The area under the curve (AUC) of the lipid-ODNs in plasma was <0.4 microg x min/mL. After complexation with LDL, plasma clearance of the lipid-ODNs was delayed. This was most evident for ODN-5, the ODN conjugated with the oleoyl ester of lithocholic acid (AUC = 6.82 +/- 1.34 microg x min/mL). The AUC of ODN-4, a cholesteryl-conjugated ODN, was 1.49 +/- 0.37 microg x min/mL. In addition, the liver uptake of the LDL-complexed lipid-ODNs was reduced. The lipid-ODNs were also administered as a complex with lactosylated LDL, a modified LDL particle that is selectively taken up by the liver. A high proportion of ODN-5 was transported to the liver along with lactosylated LDL (69.1 +/- 8.1% of the dose at 15 min after injection), whereas much less ODN-4 was transported (36.6 +/- 0.1% of the dose at 15 min after injection). We conclude that the oleoyl ester of lithocholic acid is a more potent lipid anchor than the other steroid lipid anchors. Because of the stable association, the oleoyl ester of lithocholic acid is an interesting candidate for tumor targeting of anticancer ODNs with lipoproteins.
Collapse
Affiliation(s)
- E T Rump
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, P.O. Box 9503, 2300 RA, Leiden, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Rensen PC, Jong MC, van Vark LC, van der Boom H, Hendriks WL, van Berkel TJ, Biessen EA, Havekes LM. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem 2000; 275:8564-71. [PMID: 10722695 DOI: 10.1074/jbc.275.12.8564] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Apolipoprotein E (apoE) is an important determinant for the uptake of triglyceride-rich lipoproteins and emulsions by the liver, but the intracellular pathway of apoE following particle internalization is poorly defined. In the present study, we investigated whether retroendocytosis is a unique feature of apoE as compared with apoB by studying the intracellular fate of very low density lipoprotein-sized apoE-containing triglyceride-rich emulsion particles and LDL after LDLr-mediated uptake. Incubation of HepG2 cells with [(3)H]cholesteryl oleate-labeled particles at 37 degrees C led to a rapid release of [(3)H]cholesterol within 30 min for both LDL and emulsion particles. In contrast, emulsion-derived (125)I-apoE was more resistant to degradation (>/=120 min) than LDL-derived (125)I-apoB (30 min). Incubation at 18 degrees C, which allows endosomal uptake but prevents lysosomal degradation, with subsequent incubation at 37 degrees C resulted in a time-dependent release of intact apoE from the cells (up to 14% of the endocytosed apoE at 4 h). The release of apoE was accelerated by the presence of protein-free emulsion (20%) or high density lipoprotein (26%). Retroendocytosis of intact particles could be excluded since little intact [(3)H]cholesteryl oleate was released (<3%). In contrast, the degradation of LDL was complete with virtually no secretion of intact apoB into the medium. The intracellular stability of apoE was also demonstrated after hepatic uptake in C57Bl/6 mice. Intravenous injection of (125)I-apoE and [(3)H]cholesteryl oleate-labeled emulsions resulted in efficient LDLr-mediated uptake of both components by the liver (45-50% of the injected dose after 20 min). At 1 h after injection, only 15-20% of the hepatic (125)I-apoE was degraded, whereas 75% of the [(3)H]cholesteryl oleate was hydrolyzed. From these data we conclude that following LDLr-mediated internalization by liver cells, apoE can escape degradation and can be resecreted. This sequence of events may allow apoE to participate in its hypothesized intracellular functions such as mediator of the post-lysosomal trafficking of lipids and very low density lipoprotein assembly.
Collapse
Affiliation(s)
- P C Rensen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, Sylvius Laboratory, P. O. Box 9503, 2300 RA Leiden, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
de Vrueh RL, Rump ET, van De Bilt E, van Veghel R, Balzarini J, Biessen EA, van Berkel TJ, Bijsterbosch MK. Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. Antimicrob Agents Chemother 2000; 44:477-83. [PMID: 10681306 PMCID: PMC89714 DOI: 10.1128/aac.44.3.477-483.2000] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Our aim is to selectively deliver 9-(2-phosphonylmethoxyethyl)adenine (PMEA) to parenchymal liver cells, the primary site of hepatitis B virus (HBV) infection. Selective delivery is necessary because PMEA, which is effective against HBV in vitro, is hardly taken up by the liver in vivo. Lactosylated reconstituted high-density lipoprotein (LacNeoHDL), a lipid particle that is specifically internalized by parenchymal liver cells via the asialoglycoprotein receptor, was used as the carrier. PMEA could be incorporated into the lipid moiety of LacNeoHDL by attaching, via an acid-labile bond, lithocholic acid-3alpha-oleate to the drug. The uptake of the lipophilic prodrug (PMEA-LO) by the liver was substantially increased after incorporation into LacNeoHDL. Thirty minutes after injection of [(3)H]PMEA-LO-loaded LacNeoHDL into rats, the liver contained 68.9% +/- 7.7% of the dose (free [(3)H]PMEA, <5%). Concomitantly, the uptake by the kidney was reduced to <2% of the dose (free [(3)H]PMEA, >45%). The hepatic uptake of PMEA-LO-loaded LacNeoHDL occurred mainly by parenchymal cells (88.5% +/- 8.2% of the hepatic uptake). Moreover, asialofetuin inhibited the liver association by >75%, indicating uptake via the asialoglycoprotein receptor. The acid-labile linkage in PMEA-LO, designed to release PMEA during lysosomal processing of the prodrug-loaded carrier, was stable at physiological pH but was hydrolyzed at lysosomal pH (half-life, 60 to 70 min). Finally, subcellular fractionation indicates that the released PMEA is translocated to the cytosol, where it is converted into its active diphosphorylated metabolite. In conclusion, lipophilic modification and incorporation of PMEA into LacNeoHDL improves the biological fate of the drug and may lead to an enhanced therapeutic efficacy against chronic hepatitis B.
Collapse
Affiliation(s)
- R L de Vrueh
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Biessen EA, Vietsch H, Rump ET, Fluiter K, Bijsterbosch MK, van Berkel TJ. Targeted delivery of antisense oligonucleotides to parenchymal liver cells in vivo. Methods Enzymol 1999; 314:324-42. [PMID: 10565023 DOI: 10.1016/s0076-6879(99)14113-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands
| | | | | | | | | | | |
Collapse
|
38
|
de Vrueh RL, Rump ET, Sliedregt LA, Biessen EA, van Berkel TJ, Bijsterbosch MK. Synthesis of a lipophilic prodrug of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and its incorporation into a hepatocyte-specific lipidic carrier. Pharm Res 1999; 16:1179-85. [PMID: 10468017 DOI: 10.1023/a:1018933126885] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE 9-(2-Phosphonylmethoxyethyl)adenine (PMEA), a potent inhibitor of Hepatitis B virus replication, is in vivo hardly taken up by parenchymal liver cells (the site of infection). Our aim is to examine whether lactosylated reconstituted HDL (LacNeoHDL), a lipidic particle that is specifically internalized by parenchymal liver cells, is a suitable carrier for the selective delivery of PMEA to this cell type. METHODS To incorporate PMEA into LacNeoHDL, we synthesized a lipophilic prodrug (PMEA-LO) by coupling PMEA via an acid-labile phosphonamidate bond to lithocholic acid-3alpha-oleate. RESULTS The yield of the synthesis was 52% ([3H]PMEA-LO: 24%). [3H]PMEA-LO readily incorporated into LacNeoHDL (13 molecules/particle) without affecting the size and net negative charge of the carrier. Further, incubation studies at lysosomal pH showed [3H]PMEA was completely released from the carrier whereas, at neutral pH or in plasma, appreciable release was not observed. CONCLUSIONS The conjugation of PMEA with lithocholic acid-3alpha-oleate results in a lipophilic prodrug that readily associates with Lac-NeoHDL. The association of the prodrug does not affect the physicochemical properties of the particle, and PMEA is released from the carrier at lysosomal pH. These findings indicate that by using the prodrug approach, LacNeoHDL is a suitable carrier to deliver PMEA to parenchymal liver cells.
Collapse
Affiliation(s)
- R L de Vrueh
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, The Netherlands
| | | | | | | | | | | |
Collapse
|
39
|
Biessen EA, Vietsch H, Rump ET, Fluiter K, Kuiper J, Bijsterbosch MK, van Berkel TJ. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem J 1999; 340 ( Pt 3):783-92. [PMID: 10359665 PMCID: PMC1220312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Anti-sense oligodeoxynucleotides (ODNs) hold great promise for correcting the biosynthesis of clinically relevant proteins. The potential of ODNs for modulating liver-specific genes might be increased by preventing untimely elimination and by improving the local bioavailability of ODNs in the target tissue. In the present study we have assessed whether the local ODN concentration can be enhanced by the targeted delivery of ODNs through conjugation to a ligand for the parenchymal liver cell-specific asialoglycoprotein receptor. A capped ODN (miscellaneous 20-mer sequence) was derivatized with a ligand with high affinity for this receptor, N2-[N2-(N2,N6-bis{N-[p-(beta-d-galactopyranosyloxy) anilino] thiocarbamyl}-L-lysyl)-N6-(N-{p-[beta-D -galactopyranosyloxy] anilino} thiocarbamyl)-L-lysyl]-N6-[N- (p-{beta-D-galactopyranosyloxy}anilino)thiocarbamyl]-L-lysine (L3G4) (Kd 6.5+/-0.2 nM, mean+/-S.D.). Both the uptake studies in vitro and the confocal laser scan microscopy studies demonstrated that L3G4-ODN was far more efficiently bound to and taken up by parenchymal liver cells than underivatized ODN. Studies in vivo in rats showed that hepatic uptake could be greatly enhanced from 19+/-1% to 77+/-6% of the injected dose after glycoconjugation. Importantly, specific ODN accumulation of ODN into parenchymal liver cells was improved almost 60-fold after derivatization with L3G4, and could be attributed to the asialoglycoprotein receptor. In conclusion, the scavenger receptor-mediated elimination pathway for miscellaneous ODN sequences can be circumvented by direct conjugation to a synthetic tag for the asialoglycoprotein receptor. In this manner a crucial requisite is met towards the application of ODNs in vivo to modulate the biosynthesis of parenchymal liver cell-specific genes such as those for apolipoprotein (a), cholesterol ester transfer protein and viral proteins.
Collapse
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, LACDR, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
40
|
Sliedregt LA, Rensen PC, Rump ET, van Santbrink PJ, Bijsterbosch MK, Valentijn AR, van der Marel GA, van Boom JH, van Berkel TJ, Biessen EA. Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J Med Chem 1999; 42:609-18. [PMID: 10052968 DOI: 10.1021/jm981078h] [Citation(s) in RCA: 109] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A series of glycolipids have been prepared which contain a cluster galactoside moiety with high affinity for the hepatic asialoglycoprotein receptor and a bile acid ester moiety which mediates stable incorporation into liposomes. Loading of liposomes with these glycolipids at a ratio of 5% (w/w) resulted in efficient recognition and uptake of the liposomes by the liver. Preinjection with asialofetuin almost completely inhibited the uptake, establishing that the liposomes were selectively recognized and processed by the asialoglycoprotein receptor on liver parenchymal cells. In contrast, a glycolipid content of 50% (w/w) led to a liver uptake that could not be inhibited by preinjection with asialofetuin, indicating that the liposomes were now processed by the Gal/Fuc-recognizing receptor on liver macrophages. The results presented in this study are important for future targeting of water-soluble and amphiphilic drugs, enveloped in these glycolipid-laden liposomes, to parenchymal liver cells.
Collapse
Affiliation(s)
- L A Sliedregt
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, Sylvius Laboratories, P.O. Box 9503, 2300 RA Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Rump ET, de Vrueh RL, Sliedregt LA, Biessen EA, van Berkel TJ, Bijsterbosch MK. Preparation of conjugates of oligodeoxynucleotides and lipid structures and their interaction with low-density lipoprotein. Bioconjug Chem 1998; 9:341-9. [PMID: 9576808 DOI: 10.1021/bc970176z] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The high expression level of receptors for low-density lipoprotein (LDL) on tumor cells makes LDL an attractive carrier for selective delivery of drugs to these cells. The aim of this study is to allow incorporation of oncogene-directed antisense oligodeoxynucleotides (ODNs) into the lipid moiety of LDL. Therefore, ODNs were conjugated with oleic acid, cholesterol, and several other steroid lipids. These latter steroid lipids were synthesized starting from bile acids and were varied in lipophilicity by attaching oleic acid ester structures. The lipid structures, activated as pentafluorophenyl esters, were conjugated in solution phase to 3'-amino-tailed ODNs. The ODNs conjugated with lithocholic acid, oleic acid, and cholesterol could easily be purified by reversed phase (RP)-HPLC. However, the ODNs conjugated with the oleoyl steroid ester structures irreversibly bound to the column material. These highly lipidic ODNs were separated from the nonconjugated ODN by electrophoresis in a 1% low-melting agarose gel containing 0.1% Tween 20. This method was found to be very effective in isolating the ODNs conjugated to the oleoyl steroid ester structures. The ODNs conjugated with cholesterol and the oleoyl esters of lithocholic and cholenic acid associated readily and nearly completely with LDL. However, the less lipidic ODNs and the ODN conjugated with the dioleoyl ester of chenodeoxycholic acid did not and did incompletely associate, respectively. Lithocholic acid and oleic acid are probably not sufficiently lipophilic to induce association with LDL, whereas the dioleoyl ester structure is probably too bulky and extended to allow partitioning into the lipid moiety of LDL. We conclude that several of the lipid-ODNs can associate readily with LDL, enabling delivery of oncogene-directed antisense ODNs via the LDL receptor pathway.
Collapse
Affiliation(s)
- E T Rump
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, The Netherlands
| | | | | | | | | | | |
Collapse
|
42
|
Biessen EA, Vietsch H, Kuiper J, Bijsterbosch MK, Berkel TJ. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol 1998; 53:262-9. [PMID: 9463484 DOI: 10.1124/mol.53.2.262] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The therapeutic activity of antisense oligodeoxynucleotides (ODNs) often is impaired due to premature degradation and poor ability to reach the (intra)cellular target. In this study, we addressed the in vivo fate of ODNs and characterized the major sites responsible for the clearance of intravenously injected phosphodiester ODN. On injection into rats, 32P-ODNs (miscellaneous sequences and GT-containing ODNs with variable G content) are rapidly cleared from the bloodstream (t1/2 = 0.6-0.7 min), with the liver being the main site of elimination. The contribution of the liver to ODN clearance depended on its sequence and varied considerably. Hepatic uptake tended to be lower for G-rich ODNs as a result of increased bone marrow uptake. Within the liver, both Kupffer cells (KC) and endothelial cells (EC) were responsible for 32P-ODN uptake. To elucidate the mechanism of liver uptake, 32P-ODN binding studies using isolated EC and KC were performed. Binding to both cell types seemed to be saturable, of moderate affinity, and mediated by a membrane-bound protein. The inhibition profiles of 32P-ODN binding to EC and KC by various (poly)anions were essentially equal and corresponded closely to those of 125I-acetylated low-density lipoprotein. In summary, the results indicate that scavenger receptors on nonparenchymal liver and bone marrow cells contribute to the elimination of ODNs from the bloodstream. Minor changes in ODN sequence markedly affect receptor recognition, resulting in considerable shifts in the biodistribution of antisense ODNs.
Collapse
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, 2300 RA Leiden, The Netherlands
| | | | | | | | | |
Collapse
|
43
|
Noorman F, Barrett-Bergshoeff MM, Biessen EA, van de Bilt E, van Berkel TJ, Rijken DC. Cluster mannosides can inhibit mannose receptor-mediated tissue-type plasminogen activator degradation by both rat and human cells. Hepatology 1997; 26:1303-10. [PMID: 9362376 DOI: 10.1053/jhep.1997.v26.pm0009362376] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Recently, we developed a series of cluster mannosides that were able to inhibit tissue-type plasminogen activator (t-PA) binding to the isolated mannose receptor. The mannoside with the highest affinity was able to inhibit t-PA clearance by the liver in the rat. To test whether these mannosides would also be efficient inhibitors in humans, we studied the expression of the mannose receptor in the human liver and determined the efficacy of the mannosides to inhibit mannose receptor-mediated t-PA degradation by both rat and human cells. Immunohistochemistry indicates that, like the rat, human liver endothelial cells and human Kupffer cells do express the mannose receptor. The mannosides do inhibit mannose receptor-mediated t-PA binding, association, and degradation by isolated rat liver endothelial cells and t-PA association and degradation by cultured human macrophages at similar concentrations. The cluster mannoside with six mannose residues connected with a backbone of five lysine groups (M6L5) was, like unlabeled t-PA, able to inhibit 125I-t-PA degradation in the nmol/L range, while the mannoside M5L4 inhibited 125I-t-PA degradation in the micromol/L range. The concentrations of mannoside necessary to inhibit 125I-t-PA degradation in vitro were comparable with the concentrations necessary to inhibit mannose receptor-mediated 125I-t-PA clearance in vivo. We conclude that there is no species difference between rat and humans with respect to the distribution of the mannose receptor in the liver and the affinity of the cluster mannosides, establishing the relevance of the inhibition of mannose receptor-mediated t-PA clearance by M6L5 as observed in the rat, for the human situation.
Collapse
Affiliation(s)
- F Noorman
- Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
| | | | | | | | | | | |
Collapse
|
44
|
Bijsterbosch MK, Manoharan M, Rump ET, De Vrueh RL, van Veghel R, Tivel KL, Biessen EA, Bennett CF, Cook PD, van Berkel TJ. In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 1997; 25:3290-6. [PMID: 9241243 PMCID: PMC146893 DOI: 10.1093/nar/25.16.3290] [Citation(s) in RCA: 118] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Systemically administered phosphorothioate antisense oligodeoxynucleotides can specifically affect the expression of their target genes, which affords an exciting new strategy for therapeutic intervention. Earlier studies point to a major role of the liver in the disposition of these oligonucleotides. The aim of the present study was to identify the cell type(s) responsible for the liver uptake of phosphorothioate oligodeoxynucleotides and to examine the mechanisms involved. In our study we used ISIS-3082, a phosphorothioate antisense oligodeoxynucleotide specific for murine ICAM-1. Intravenously injected [3H]ISIS-3082 (dose: 1 mg/kg) was cleared from the circulation of rats with a half-life of 23.3+/-3.8 min. At 90 min after injection (>90% of [3H]ISIS-3082 cleared), the liver contained the most radioactivity, whereas the second-highest amount was recovered in the kidneys (40.5+/-1.4% and 17.9+/-1.3% of the dose, respectively). Of the remaining tissues, only spleen and bone marrow actively accumulated [3H]ISIS-3082. By injecting different doses of [3H]ISIS-3082, it was found that uptake by liver, spleen, bone marrow, and kidneys is saturable, which points to a receptor-mediated process. Subcellular fractionation of the liver indicates that ISIS-3082 is internalized and delivered to the lysosomes. Liver uptake occurs mainly (for 56.1+/-3.0%) by endothelial cells, whereas parenchymal and Kupffer cells account for 39.6+/-4.5 and 4.3+/-1.7% of the total liver uptake, respectively. Preinjection of polyinosinic acid substantially reduced uptake by liver and bone marrow, whereas polyadenylic acid was ineffective, which indicates that in these tissues scavenger receptors are involved in uptake. Polyadenylic acid, but not polyinosinic acid, reduced uptake by kidneys, which suggests renal uptake by scavenger receptors different from those in the liver. We conclude that scavenger receptors on rat liver endothelial cells play a predominant role in the plasma clearance of ISIS-3082. As scavenger receptors are also expressed on human endothelial liver cells, our findings are probably highly relevant for the therapeutic application of phosphorothioate oligodeoxynucleotides in humans. If the target gene is not localized in endothelial liver cells, the therapeutic effectiveness might be improved by developing delivery strategies that redirect the oligonucleotides to the actual target cells.
Collapse
Affiliation(s)
- M K Bijsterbosch
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, PO Box 9503, 2300 RA Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Biessen EA, van Teijlingen M, Vietsch H, Barrett-Bergshoeff MM, Bijsterbosch MK, Rijken DC, van Berkel TJ, Kuiper J. Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation 1997; 95:46-52. [PMID: 8994415 DOI: 10.1161/01.cir.95.1.46] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Clinical application of tissue plasminogen activator (TPA) as a fibrinolytic agent is complicated by its rapid clearance from the bloodstream, which is caused by TPA liver uptake. The mannose receptor on endothelial liver cells and the LDL receptor-related protein (LRP) on parenchymal liver cells were reported to contribute to liver uptake. METHODS AND RESULTS In this study, we addressed whether TPA clearance can be delayed by inhibiting receptor-mediated endocytosis of TPA. A series of cluster mannosides was synthesized, and their affinity for the mannose receptor was determined. A cluster mannoside carrying six mannose groups (M6L5) displayed a subnanomolar affinity for the mannose receptor (Ki = 0.41 +/- 0.09 nmol/L). Preinjection of M6L5 (1.2 mg/kg) reduced the clearance of 125I-TPA in rats by 60% because of specific inhibition of the endothelial cell uptake. The low toxicity of M6L5, combined with its accessible synthesis and high specificity for the mannose receptor, makes it a promising agent to improve the pharmacokinetics of TPA. Blockade of LRP by 39-kD receptor-associated protein (GST-RAP) also inhibited TPA clearance by 60%. Finally, combined preinjection of M6L5 and GST-RAP almost completely abolished reduced liver uptake of TPA and delayed its clearance by a factor of 10. CONCLUSIONS It can be concluded that (1) the mannose receptor and LRP appear to be the sole major receptors responsible for TPA clearance and (2) therapeutic levels of TPA can be maintained for a prolonged time span by coadministration of the aforementioned receptor antagonists.
Collapse
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Biessen EA, Sliedregt LA, Van Berkel TJ. Approaches for the design of novel anti-atherogenic compounds. Subcell Biochem 1997; 28:507-39. [PMID: 9090305 DOI: 10.1007/978-1-4615-5901-6_17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, Leiden-Amsterdam Center for Drug Research, Sylvius Laboratory, University of Leiden, The Netherlands
| | | | | |
Collapse
|
47
|
Biessen EA, Vietsch H, van Berkel TJ. Induction of hepatic uptake of lipoprotein(a) by cholesterol-derivatized cluster galactosides. Arterioscler Thromb Vasc Biol 1996; 16:1552-8. [PMID: 8977461 DOI: 10.1161/01.atv.16.12.1552] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We have previously developed triantennary galactosides [TG(4A)C and TG(20A)C] that lower cholesterol levels by inducing liver uptake of lipoproteins via galactose-recognizing hepatic receptors. In this study, we have investigated whether this strategy could also be applied to reduce elevated serum levels of the atherogenic lipoprotein(a) [Lp(a)]. Both TG(4A)C and TG(20A)C could be incorporated into Lp(a). Incorporation of these glycolipids induced a rapid clearance of Lp(a). Concomitantly, the hepatic uptake of 125I-Lp(a) was enhanced from 4 +/- 1% to 80 +/- 4% of the injected dose for TG(4A)C (P < .0001) and to 17 +/- 4% of the injected dose for TG(20A)C (P < .006). TG(4A)C was apparently more effective in accelerating the serum decay of 125I-Lp(a), which may be caused by the higher hydrophobicity of this glycolipid relative to TG(20A)C. The TG(4A)C- and TG(20A)C-induced stimulation of the serum decay and liver uptake of 125I-Lp(a) could be significantly inhibited (> 85%) by preinjection of N-acetyl-galactosamine (150 mg), indicating that galactose-recognizing receptors are involved in the liver uptake of the glycolipid/Lp(a) complexes. The TG(4A)C-induced liver uptake of 125I-Lp(a) could be ascribed mainly to Kupffer cells (76 +/- 7%), whereas the parenchymal liver cell was the major site for liver uptake of TG(20A)C-laden 125I-Lp(a) (55 +/- 12%). In conclusion, both TG(4A)C and TG(20A)C stimulate the catabolism of 125I-Lp(a) by enhancing hepatic uptake. Because endocytosis of the substrate via galactose-recognizing receptors on Kupffer and parenchymal liver cells is followed by lysosomal degradation, we anticipate that both approaches for Lp(a) targeting may prove valuable as therapeutic modalities for lowering atherogenic levels of Lp(a).
Collapse
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands
| | | | | |
Collapse
|
48
|
Biessen EA, Noorman F, van Teijlingen ME, Kuiper J, Barrett-Bergshoeff M, Bijsterbosch MK, Rijken DC, van Berkel TJ. Lysine-based cluster mannosides that inhibit ligand binding to the human mannose receptor at nanomolar concentration. J Biol Chem 1996; 271:28024-30. [PMID: 8910412 DOI: 10.1074/jbc.271.45.28024] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
In search of synthetic high affinity ligands for the mannose receptor, we synthesized a series of lysine-based oligomannosides containing two (M2L) to six (M6L5) terminal alpha-D-mannose groups that are connected with the backbone by flexible elongated spacers (16 A). The synthesized cluster mannosides were all able to displace binding of biotinylated ribonuclease B and tissue-type plasminogen activator to isolated human mannose receptor. The affinity of these cluster mannosides for the mannose receptor was continuously enhanced from 18-23 microM to 0.5-2.6 nM, with mannose valencies increasing from two to six. On average, expansion of the cluster mannoside with an additional alpha-D-mannose group resulted in a 10-fold increase in its affinity for the mannose receptor. M3L2 to M6L5 displayed negative cooperative inhibition of ligand binding to the mannose receptor, suggesting that binding of these mannosides involves multiple binding sites. The nanomolar affinity of the most potent ligand, the hexamannoside M6L5 makes it the most potent synthetic cluster mannoside for the mannose receptor yet developed. As a result of its high affinity and accessible synthesis, M6L5 not only is a powerful tool to study the mechanism of ligand binding by the mannose receptor, but it is also a promising targeting device to accomplish cell-specific delivery of genes and drugs to liver endothelial cells or macrophages in bone marrow, lungs, spleen, and atherosclerotic plaques.
Collapse
Affiliation(s)
- E A Biessen
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, P.O. Box 9503, 2300 RA Leiden, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Fluiter K, Vietsch H, Biessen EA, Kostner GM, van Berkel TJ, Sattler W. Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells. Biochem J 1996; 319 ( Pt 2):471-6. [PMID: 8912683 PMCID: PMC1217792 DOI: 10.1042/bj3190471] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Oxidation of low-density lipoprotein (LDL) leads initially to the formation of LDL-associated cholesteryl ester hydroperoxides (CEOOH). LDL-associated CEOOH can be transferred to high-density lipoprotein (HDL), and HDL-associated CEOOH are rapidly reduced to the corresponding hydroxides (CEOH) by an intrinsic peroxidase-like activity. We have now performed in vivo experiments to quantify the clearance rates and to identify the uptake sites of HDL-associated [3H]Ch18:2-OH in rats. Upon injection into rats, HDL-associated [3H]Ch18:2-OH is removed more rapidly from the circulation than HDL-associated [3H]Ch18:2. Two minutes after administration of [3H]Ch18:2-OH-HDL, 19.6 +/- 2.6% (S.E.M.; n = 4) of the label was taken up by the liver as compared with 2.4 +/- 0.25% (S.E.M.; n = 4) for [3H]Ch18:2-HDL. Organ distribution studies indicated that only the liver and adrenals exhibited preferential uptake of [3H]Ch18:2-OH as compared with [3H]Ch18:2, with the liver as the major site of uptake. A cell-separation procedure, employed 10 min after injection of [3H]Ch18:2-OH-HDL or [3H]Ch18:2-HDL, demonstrated that within the liver only parenchymal cells take up HDL-CE by the selective uptake pathway. Selective uptake by parenchymal cells of [3H]Ch18:2-OH was 3-fold higher than that of [3H]Ch18:2, while Kupffer and endothelial cell uptake of the lipid tracers reflected HDL holoparticle uptake (as analysed with iodinated versus cholesteryl ester-labelled HDL). The efficient uptake of [3H]Ch18:2-OH by parenchymal cells was coupled to a 3-fold increase in rate of radioactive bile acid secretion from [3H]Ch18:2-OH-HDL as compared with [3H]Ch18:2-HDL. In vitro studies with freshly isolated parenchymal cells showed that the association of [3H]Ch18:2-OH-HDL at 37 degrees C exceeded [3H]Ch18:2-HDL uptake almost 4-fold. Our results indicate that HDL-associated CEOH are efficiently and selectively removed from the blood circulation by the liver in vivo. The selective liver uptake is specifically exerted by parenchymal cells and coupled to a rapid biliary secretion pathway. The liver uptake and biliary secretion route may allow HDL to function as an efficient protection system against potentially atherogenic CEOOH.
Collapse
Affiliation(s)
- K Fluiter
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, University of Leiden, Sylvius Laboratories, The Netherlands
| | | | | | | | | | | |
Collapse
|
50
|
Kuiper J, Van't Hof A, Otter M, Biessen EA, Rijken DC, van Berkel TJ. Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions. Biochem J 1996; 313 ( Pt 3):775-80. [PMID: 8611154 PMCID: PMC1216977 DOI: 10.1042/bj3130775] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The fibrin-specific thrombolyticum tissue-type plasminogen activator (t-PA) has proven to be a potent drug in several clinical trials, but its clinical application is complicated by the rapid clearance of t-PA from the circulation. The rapid plasma clearance of t-PA results from the uptake of t-PA in the liver. t-PA consists of several domains which may be involved in the interaction with the liver. Three domain-deletion mutants, which were produced by the use of a cassette gene system, were studied in vivo and in vitro for their capacity to bind to the various types of rat liver cells. The three mutants lacked, in comparison to control t-PA, the epidermal growth factor (G) domain, the finger (F) domain or the G domain plus the first kringle (K1). The plasma clearance of the three mutants was slower than that of control t-PA. The slower plasma clearance resulted from a decreased liver uptake: 50 and 80% for t-PA mutants and control t-PA respectively. It was found that the K1 domain was of major importance for the uptake of t-PA by liver endothelial cells in vivo and in vitro. The high-affinity binding of t-PA (and t-PA mutants) to parenchymal liver cells depended largely on the presence of the G domain. Other domain(s), like the F, K2 or protease domain, may be responsible for low-affinity, t-PA-specific binding to rat parenchymal liver cells.
Collapse
Affiliation(s)
- J Kuiper
- Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius laboratory, The Netherlands
| | | | | | | | | | | |
Collapse
|